UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, ~~2017.~~2020.

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from to .

Commission file number: 001-35347

Clovis Oncology, Inc.

(Exact name of Registrant as specified in its charter)


Delaware	90-0475355
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

5500 Flatiron Parkway, Suite 100
Boulder, Colorado	80301
(Address of principal executive offices)	(Zip Code)

~~(303)~~ (303) 625-5000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act


Title of Each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock par Value $0.001 per share	CLVS	The NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐◻

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes ☒⌧ No ☐◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐⌧		Accelerated filer	☒◻
Non-accelerated filer	☐◻	~~(Do not check if a smaller reporting company)~~	Smaller reporting company	☐
			Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of October ~~27, 2017~~30, 2020 was ~~49,014,867.~~88,318,959.

Table of Contents

CLOVIS ONCOLOGY, INC.

FORM 10-Q

TABLE OF CONTENTS



PART I. Financial Information			3

~~PART I. Financial Information~~ITEM 1.	3
		Financial Statements (unaudited)	3
~~ITEM 1.~~		~~Financial Statements (unaudited)~~	3

		Consolidated Statements of Operations and Comprehensive Loss — for the three and nine months ended September 30, ~~2017~~2020 and ~~2016~~September 30, 2019	3


		Consolidated Balance Sheets — as of September 30, ~~2017~~2020 and December 31, ~~2016~~2019	4


		Consolidated Statements of Stockholders’ Equity (Deficit) – for the nine months ended September 30, 2020	5

		Consolidated Statements of Stockholders’ Equity (Deficit) – for the nine months ended September 30, 2019	6

		Consolidated Statements of Cash Flows — for the nine months ended September 30, ~~2017~~2020 and ~~2016~~2019	5
			7

		Notes to Unaudited Consolidated Financial Statements	6 8

ITEM 2.		Management’s Discussion and Analysis of Financial Condition and Results of Operations	21 30

ITEM 3.		Quantitative and Qualitative Disclosures About Market Risk	33 47

ITEM 4.		Controls and Procedures	34 47

PART II. Other Information			35 49

ITEM 1.		Legal Proceedings	35 49

ITEM 1A.		Risk Factors	38 50

ITEM 2.		Unregistered Sales of Equity Securities and Use of Proceeds	38 52

ITEM 3.		Defaults Upon Senior Securities	38 52

ITEM 4.		Mine Safety Disclosures	38 52

ITEM 5.		Other Information	38 52

ITEM 6.		Exhibits	38 52

SIGNATURES			42 57

Table of Contents

PART I. FINANCIAL INFORMATION

~~ITEM 1.FINANCIAL STATEMENTS~~
ITEM 1.
FINANCIAL STATEMENTS

CLOVIS ONCOLOGY, INC.

Consolidated Statements of Operations and Comprehensive Loss

~~CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS~~(Unaudited)

~~(Unaudited)~~

(In thousands, except per share amounts)

Three months ended September 30,

Nine months ended September 30,


2017

2016

2017

2016

(in thousands, except per share amounts)

Product revenue, net

$
16,806

$
—

$
38,471

$
—

Operating expenses:









Cost of sales - product

3,026

—

6,920

—

Cost of sales - intangible asset amortization

372

—

1,115

—

Research and development

38,924

54,338

104,479

196,675

Selling, general and administrative

35,011

9,162

100,384

28,541

Acquired in-process research and development

—

500

—

800

Impairment of intangible asset

—

—

—

104,517

Change in fair value of contingent purchase consideration

—

—

—

(24,936)

Total expenses

77,333

64,000

212,898

305,597

Operating loss

(60,527)

(64,000)

(174,427)

(305,597)

Other income (expense):









Interest expense

(2,618)

(2,108)

(7,796)

(6,318)

Foreign currency loss

(44)

(66)

(127)

(434)

Legal settlement loss, net of insurance receivable

—

—

(117,000)

—

Other income

1,291

252

2,237

473

Other expense, net

(1,371)

(1,922)

(122,686)

(6,279)

Loss before income taxes

(61,898)

(65,922)

(297,113)

(311,876)

Income tax benefit

1,234

227

2,599

33,467

Net loss

$
(60,664)

$
(65,695)

$
(294,514)

$
(278,409)

Other comprehensive income:











Foreign currency translation adjustments, net of tax

1,595


58

4,874


2,190

Net unrealized gain (loss) on available-for-sale securities, net of tax

10


(18)

5


260

Other comprehensive income

1,605


40

4,879


2,450

Comprehensive loss

$
(59,059)

$
(65,655)

$
(289,635)

$
(275,959)

Loss per basic and diluted common share:

Basic and diluted net loss per common share

$
(1.24)

$
(1.70)

$
(6.39)

$
(7.24)

Basic and diluted weighted average common shares outstanding

48,917

38,538

46,062

38,429


	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019

	(in thousands, except per share amounts)				(in thousands, except per share amounts)
Revenues:
Product revenue	$	38,772	$	37,603	$	121,223	$	103,699
Operating expenses:
Cost of sales - product		8,438		8,134		26,654		21,984
Cost of sales - intangible asset amortization		1,343		1,212		3,834		3,549
Research and development		62,902		77,896		201,000		210,674
Selling, general and administrative		38,636		41,811		123,136		137,601
Acquired in-process research and development		—		9,440		—		9,440
Other operating expenses		—		5,539		3,805		5,539
Total expenses		111,319		144,032		358,429		388,787
Operating loss		(72,547)		(106,429)		(237,206)		(285,088)
Other income (expense):
Interest expense		(6,859)		(5,278)		(23,160)		(12,684)
Foreign currency gain (loss)		633		(229)		(102)		(648)
Gain on extinguishment of debt		—		18,480		—		18,480
Loss on convertible senior notes conversion		—		—		(7,791)		—
Loss on extinguishment of debt		—		—		(3,277)		—
Legal settlement loss		—		(1,750)		—		(26,750)
Other income		79		781		1,160		5,081
Other income (expense), net		(6,147)		12,004		(33,170)		(16,521)
Loss before income taxes		(78,694)		(94,425)		(270,376)		(301,609)
Income tax benefit		18		350		122		686
Net loss		(78,676)		(94,075)		(270,254)		(300,923)
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax		254		(143)		212		(149)
Net unrealized (loss) gain on available-for-sale securities, net of tax		—		(68)		(6)		84
Other comprehensive income (loss):		254		(211)		206		(65)
Comprehensive loss	$	(78,422)	$	(94,286)	$	(270,048)	$	(300,988)

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(0.89)	$	(1.72)	$	(3.37)	$	(5.62)
Basic and diluted weighted average common shares outstanding		88,255		54,707		80,153		53,549

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

CLOVIS ONCOLOGY, INC.

Consolidated Balance Sheets

~~CONSOLIDATED BALANCE SHEETS~~(Unaudited)

~~(Unaudited)~~

(In thousands, except for share amounts)

September 30,

December 31,


2017

2016

ASSETS





Current assets:





Cash and cash equivalents

$
611,472

$
216,186

Accounts receivable, net

—

121

Insurance receivable

25,000

—

Inventories

5,345

—

Available-for-sale securities

16,499

49,997

Prepaid research and development expenses

2,853

6,427

Deposit on inventory

31,818

—

Other current assets

5,911

6,679

Total current assets

698,898

279,410

Property and equipment, net

4,070

4,440

Intangible assets, net

19,932

21,047

Goodwill

64,253

57,192

Other assets

18,206

2,468

Total assets

$
805,359

$
364,557

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)





Current liabilities:





Accounts payable

$
14,308

$
10,912

Accrued research and development expenses

21,344

35,198

Deferred revenue

2,755

—

Milestone liability

21,511

20,062

Accrued liability for legal settlement

142,000

—

Other accrued expenses

17,467

19,487

Total current liabilities

219,385

85,659

Deferred income taxes, net

421

—

Convertible senior notes

282,082

281,126

Deferred rent, long-term

4,282

1,406

Total liabilities

506,170

368,191

Commitments and contingencies (Note 14)





Stockholders' equity (deficit):





Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2017 and December 31, 2016

—

—

Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2017 and December 31, 2016; 49,002,468 and 38,724,090 shares issued and outstanding at September 30, 2017 and December 31, 2016 respectively

49

39

Additional paid-in capital

1,767,397

1,174,950

Accumulated other comprehensive loss

(42,701)

(47,580)

Accumulated deficit

(1,425,556)

(1,131,043)

Total stockholders' equity (deficit)

299,189

(3,634)

Total liabilities and stockholders' equity (deficit)

$
805,359

$
364,557


	September 30,		December 31,
	2020		2019

ASSETS
Current assets:
Cash and cash equivalents	$	224,702	$	161,833
Accounts receivable, net		20,265		20,562
Inventories, net		24,626		26,519
Available-for-sale securities		—		134,826
Prepaid research and development expenses		3,418		3,881
Other current assets		16,268		18,847
Total current assets		289,279		366,468
Inventories		109,448		98,053
Deposit on inventory		—		12,350
Property and equipment, net		12,808		15,287
Right-of-use assets, net		31,262		28,141
Intangible assets, net		67,086		62,920
Goodwill		63,074		63,074
Other assets		20,100		23,311
Total assets	$	593,057	$	669,604
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	35,495	$	32,237
Accrued research and development expenses		43,084		53,214
Lease liabilities		4,975		5,405
Other accrued expenses		40,404		42,228
Total current liabilities		123,958		133,084
Long-term lease liabilities - less current portion		32,652		29,479
Convertible senior notes		505,278		644,751
Borrowings under financing agreement		92,108		34,991
Other long-term liabilities		2,427		1,556
Total liabilities		756,423		843,861
Commitments and contingencies (Note 15)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2020 and December 31, 2019		—		—
Common stock, $0.001 par value per share, 200,000,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 88,309,067 and 54,956,341 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		88		55
Additional paid-in capital		2,394,975		2,114,068
Accumulated other comprehensive loss		(44,659)		(44,865)
Accumulated deficit		(2,513,770)		(2,243,515)
Total stockholders' deficit		(163,366)		(174,257)
Total liabilities and stockholders' equity (deficit)	$	593,057	$	669,604

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

CLOVIS ONCOLOGY, INC.

Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)


						Accumulated
				Additional		Other
	Common Stock			Paid-In		Comprehensive		Accumulated
	Shares	Amount		Capital		Income (Loss)		Deficit		Total

	(in thousands, except for share amounts)
January 1, 2020	54,956,341	$	55	$	2,114,068	$	(44,865)	$	(2,243,515)	$	(174,257)
Exercise of stock options	759		—		2		—		—		2
Issuance of common stock from vesting of restricted stock units	662,323		—		—		—		—		—
Share-based compensation expense	—		—		12,961		—		—		12,961
Net unrealized gain on available-for-sale securities	—		—		—		78		—		78
Foreign currency translation adjustments	—		—		—		(103)		—		(103)
Convertible senior notes conversion	17,877,164		18		133,640		—		—		133,658
Net loss	—		—		—		—		(99,332)		(99,332)
March 31, 2020	73,496,587		73		2,260,671		(44,890)		(2,342,847)		(126,993)
Exercise of stock options	6,661		—		(41)		—		—		(41)
Issuance of common stock from vesting of restricted stock units	113,461		—		—		—		—		—
Issuance of common stock under employee stock purchase plan	158,126		—		907		—		—		907
Share-based compensation expense	—		—		13,313		—		—		13,313
Net unrealized loss on available-for-sale securities	—		—		—		(84)		—		(84)
Foreign currency translation adjustments	—		—		—		61		—		61
Issuance of common stock, net of issuance costs	11,090,000		11		83,416		—		—		83,427
Convertible senior notes conversion	3,331,870		4		24,278		—		—		24,282
Net loss	—		—		—		—		(92,247)		(92,247)
June 30, 2020	88,196,705		88		2,382,544		(44,913)		(2,435,094)		(97,375)
Exercise of stock options	—		—		—		—		—		—
Issuance of common stock from vesting of restricted stock units	112,362		—		—		—		—		—
Share-based compensation expense	—		—		12,491		—		—		12,491
Net unrealized gain (loss)on available-for-sale securities	—		—		—		—		—		—
Foreign currency translation adjustments	—		—		—		254		—		254
Other financing costs	—		—		(60)		—		—		(60)
Net loss	—		—		—		—		(78,676)		(78,676)
September 30, 2020	88,309,067	$	88	$	2,394,975	$	(44,659)	$	(2,513,770)	$	(163,366)

Table of Contents

CLOVIS ONCOLOGY, INC.

Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)


						Accumulated
				Additional		Other
	Common Stock			Paid-In		Comprehensive		Accumulated
	Shares	Amount		Capital		Income (Loss)		Deficit		Total

	(in thousands, except for share amounts)
January 1, 2019	52,797,516	$	53	$	2,034,142	$	(44,634)	$	(1,843,092)	$	146,469
Exercise of stock options	83,132		—		1,093		—		—		1,093
Issuance of common stock from vesting of restricted stock units	113,402		—		—		—		—		—
Share-based compensation expense	—		—		13,639		—		—		13,639
Net unrealized gain on available-for-sale securities	—		—		—		75		—		75
Foreign currency translation adjustments	—		—		—		(5)		—		(5)
Net loss	—		—		—		—		(86,420)		(86,420)
March 31, 2019	52,994,050		53		2,048,874		(44,564)		(1,929,512)		74,851
Exercise of stock options	20,741		—		223		—		—		223
Issuance of common stock from vesting of restricted stock units	63,413		—		—		—		—		—
Issuance of common stock under employee stock purchase plan	92,275		—		1,166		—		—		1,166
Share-based compensation expense	—		—		14,130		—		—		14,130
Net unrealized gain on available-for-sale securities	—		—		—		77		—		77
Foreign currency translation adjustments	—		—		—		(1)		—		(1)
Net loss	—		—		—		—		(120,426)		(120,426)
June 30, 2019	53,170,479	$	53	$	2,064,393	$	(44,488)	$	(2,049,938)	$	(29,980)
Exercise of stock options	84,482		—		45		—		—		45
Issuance of common stock from vesting of restricted stock units	68,506		—		—		—		—		—
Share-based compensation expense	—		—		13,979		—		—		13,979
Net unrealized loss on available-for-sale securities	—		—		—		(68)		—		(68)
Foreign currency translation adjustments	—		—		—		(143)		—		(143)
Litigation settlement	1,482,058		2		22,745		—		—		22,747
Net loss	—		—		—		—		(94,075)		(94,075)
September 30, 2019	54,805,525	$	55	$	2,101,162	$	(44,699)	$	(2,144,013)	$	(87,495)

See accompanying Notes to Unaudited Consolidated Financial Statements

Table of Contents

CLOVIS ONCOLOGY, INC.

CONSOLIDATED STATEMENTS OF CASH ~~FLOWS~~FLOWS

(Unaudited)

(In thousands)

Nine months ended September 30,


2017

2016

Operating activities





Net loss

$
(294,514)

$
(278,409)

Adjustments to reconcile net loss to net cash used in operating activities:





Share-based compensation expense

32,201

29,744

Depreciation and amortization

1,911

819

Amortization of premiums and discounts on available-for-sale securities

6

190

Amortization of debt issuance costs

956

928

Legal settlement loss, net of insurance receivable

117,000

—

Impairment of intangible asset

—

104,517

Change in fair value of contingent purchase consideration

—

(24,661)

Loss on disposal of property and equipment

—

105

Deferred income taxes

(2,403)

(33,320)

Changes in operating assets and liabilities:



Accounts receivable

121

—

Inventory

(5,345)

—

Prepaid and accrued research and development expenses

(16,284)

(14,877)

Deposit on inventory

(31,818)

—

Other operating assets

(4,156)

2,358

Accounts payable

5,050

(322)

Other accrued expenses

1,949

923

Net cash used in operating activities

(195,326)

(212,005)

Investing activities





Purchases of property and equipment

(416)

(761)

Deposits for purchases of property and equipment

(2,515)

65

Purchases of available-for-sale securities

(180,000)

—

Maturities of available-for-sale securities

213,500

175,000

Acquired in-process research and development - milestone payment

(1,100)

—

Net cash provided by investing activities

29,469

174,304

Financing activities





Proceeds from the sale of common stock, net of issuance costs

545,838

—

Proceeds from the exercise of stock options and employee stock purchases

14,419

2,602

Net cash provided by financing activities

560,257

2,602

Effect of exchange rate changes on cash and cash equivalents

886

67

Increase (decrease) in cash and cash equivalents

395,286

(35,032)

Cash and cash equivalents at beginning of period

216,186

278,756

Cash and cash equivalents at end of period

$
611,472

$
243,724

Supplemental disclosure of cash flow information:





Cash paid for interest

$
7,188

$
7,188

Non-cash investing and financing activities:





Vesting of restricted stock units

$
9,449

$
157


	Nine months ended September 30,
	2020		2019

Operating activities
Net loss	$	(270,254)	$	(300,923)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense		38,765		41,748
Depreciation and amortization		6,147		5,727
Amortization of premiums and discounts on available-for-sale securities		(174)		(1,269)
Amortization of debt issuance costs		2,068		2,070
Write-off of debt issuance costs related to convertible senior notes transactions		4,344		—
Gain on extinguishment of debt		—		(18,480)
Loss on convertible senior notes conversion		7,791		—
Loss on extinguishment of debt		3,277		—
Legal settlement loss		—		22,747
Acquired in-process research and development		—		9,440
Loss on sale of property and equipment		—		783
Changes in operating assets and liabilities:
Accounts receivable		315		(3,952)
Inventory		8,694		(22,952)
Prepaid and accrued research and development expenses		(8,270)		13,293
Other operating assets and liabilities		4,655		(5,979)
Accounts payable		(2,247)		2,384
Other accrued expenses		8,214		1,895
Net cash used in operating activities		(196,675)		(253,468)
Investing activities
Purchases of property and equipment		(94)		(2,887)
Proceeds from sale of property and equipment		—		275
Purchases of available-for-sale securities		(9,962)		(335,104)
Sales of available-for-sale securities		144,644		480,097
Acquired in-process research and development - milestone payment		(8,000)		(15,750)
Net cash provided by investing activities		126,588		126,631
Financing activities
Proceeds from sale of common stock, net of issuance costs		246,668		—
Proceeds from issuance of convertible senior notes, net of issuance costs		—		254,965
Payment of convertible senior notes		(164,443)		—
Extinguishment of convertible senior notes		—		(169,853)
Proceeds from borrowings under ATHENA financing agreement		49,963		19,044
Proceeds from the exercise of stock options and employee stock purchases		868		2,526
Payments on finance leases		(1,092)		—
Payments on other long-term liabilities		(156)		—
Net cash provided by financing activities		131,808		106,682
Effect of exchange rate changes on cash and cash equivalents		1,148		(240)
Increase (decrease) in cash and cash equivalents		62,869		(20,395)
Cash and cash equivalents at beginning of period		161,833		221,876
Cash and cash equivalents at end of period	$	224,702	$	201,481
Supplemental disclosure of cash flow information:
Cash paid for interest	$	10,200	$	8,640
Non-cash investing and financing activities:
Vesting of restricted stock units	$	6,885	$	4,735

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

CLOVIS ONCOLOGY, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of Business and Basis of Presentation

Clovis Oncology, Inc. (together with its consolidated subsidiaries, the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and ~~other~~additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. We have and intend to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in ~~one~~1 segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate ~~activities.~~activities and since 2016 we have also marketed and sold products.

~~On December 19, 2016, the FDA approved~~Our marketed product Rubraca® (rucaparib) ~~tablets as monotherapy~~, an oral small molecule inhibitor of poly ADP-ribose polymerase (“PARP”), is marketed in the United States for 2 indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and also an indication specific to metastatic castration-resistant prostate cancer (“mCRPC”). The initial indication received approval from the United States Food and Drug Administration (“FDA”) in December 2016 and covers the treatment of adult patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) ~~associated advanced~~-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with ~~two~~2 or more chemotherapies and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. In April 2018, the FDA also approved Rubraca for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The approval in this second, broader and earlier-line indication on a priority review timeline was based on positive data from the phase 3 ARIEL3 clinical trial. Diagnostic testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

In May 2018, the European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with 2 or more prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum-based chemotherapy. In January 2019, the European Commission granted a variation to the marketing authorization to include the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. With this approval, Rubraca is now authorized in the EU for certain patients in the recurrent ovarian cancer maintenance setting regardless of their BRCA mutation status. Following successful reimbursement negotiations, we have launched Rubraca in each of Germany, United Kingdom, Italy, France and Spain.

In May 2020, the FDA approved Rubraca tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated mCRPC who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The FDA approved this indication under accelerated approval based on objective response rate and duration of response data from the multi-center, single arm TRITON2 clinical trial. We ~~began selling~~have launched Rubraca for prostate cancer in the U.S. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. The TRITON3 clinical trial is expected to serve as the ~~fourth quarter~~confirmatory study for the Rubraca accelerated approval in mCRPC. In August 2020, the FDA approved the use of ~~2016. Rucaparib~~Foundation Medicine’s plasma diagnostic detection of deleterious BRCA mutation (germline and/or somatic) to select mCRPC patients for treatment with Rubraca.

Beyond our labeled indications, we have a clinical development program underway to further evaluate Rubraca in a variety of solid tumor types, either as monotherapy or in combination with other agents, including several studies as part of our ongoing clinical collaboration with Bristol Myers Squibb Company (“Bristol Myers Squibb”) to evaluate its immunotherapy OPDIVO® (nivolumab) in combination with Rubraca. We initiated the Phase 2 LODESTAR study in December 2019 to evaluate Rubraca in homologous recombination repair genes across tumor types. The study is ~~being studied~~

Table of Contents

evaluating rucaparib as monotherapy treatment in patients with recurrent solid tumors associated with a ~~potential maintenance therapy for ovarian cancer patients~~deleterious mutation in the ARIEL3 trial. On June 19, 2017, we announced that the ARIEL3 trial successfully achieved the primary endpoint of improved progression-free survival (“PFS”) by investigator review in each of three populations studied. PFS was also improved in the rucaparib group compared with placebo by blinded independent central review (“BICR”), a key secondary endpoint.homologous recombination repair genes. Based on ~~these findings,~~our interactions with the FDA, we ~~submitted~~believe that this study may be registration-enabling for a targeted gene- and tumor-agnostic label, if data from the trial support the potential for an accelerated approval. Assuming enrollment in this study continues as planned, we may potentially file a supplemental New Drug Application with the FDA for this indication in the second half of 2021. We hold worldwide rights to Rubraca.

In addition to Rubraca, we have a second product candidate currently in clinical development. Lucitanib is an investigational, oral, potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors 1 through 3 (“~~sNDA”~~VEGFR1-3”), platelet-derived growth factor receptors alpha and beta (“PDGFR α/β”) ~~in October 2017~~and fibroblast growth factor receptors 1 through 3 (“FGFR1-3”). We believe that data for a ~~second-line or later maintenance treatment indication~~drug similar to lucitanib that inhibits these same pathways – when combined with a PD-1 inhibitor – represent a scientific rationale for ~~all women~~development of lucitanib in combination with ~~platinum-sensitive~~a PD-1 inhibitor, and in February 2019, lucitanib was added to our clinical collaboration with Bristol Myers Squibb. Encouraging data of VEGF and PARP inhibitors in combination also supports the evaluation of lucitanib combined with Rubraca. Thus, we have two Phase 1b/2 combination studies involving lucitanib underway, which consist of the following: the Clovis-sponsored LIO-1 study of lucitanib in combination with nivolumab in advanced solid tumors and gynecologic cancers, which is currently enrolling patients in the Phase 2 part of the study; and an arm of the Clovis-sponsored SEASTAR study evaluating lucitanib in combination with Rubraca in advanced solid tumors and ovarian ~~cancer who have responded~~cancer. We expect to ~~their most recent platinum therapy.~~present interim data from the Clovis-sponsored LIO-1 study of lucitanib in combination with nivolumab at medical meetings in 2021. We hold the global (excluding China) development and commercialization rights for lucitanib.

~~Our Marketing Authorization Application~~In September 2019, we entered into a license and collaboration agreement with 3B Pharmaceuticals GmbH (“~~MAA”~~3BP”) to develop a peptide-targeted radionuclide therapy (“PTRT”) and imaging agent targeting fibroblast-activating protein alpha (“FAP”).

Following completion of preclinical work to support an investigational new drug application (“IND”) for ~~rucaparib that~~the lead candidate under our license and collaboration agreement, designated internally as FAP-2286, we ~~submitted~~plan to ~~the European Medicines Agency (“EMA”) for an ovarian cancer treatment indication is currently under review.~~conduct a broad clinical development program. We anticipate submitting two INDs for FAP-2286 for use as imaging and treatment agents, respectively, in Q4 2020 to support an ~~opinion from~~initial Phase 1 study to determine the ~~Committee~~dose and tolerability of FAP-2286 as a therapeutic agent with expansion cohorts planned in multiple tumor types as part of a global development program. The FAP-targeting imaging agent will be utilized to identify tumors that contain FAP for ~~Medicinal Products for Human Use (“CHMP”)~~treatment in ~~late 2017, and, if we receive a favorable opinion from~~ the CHMP, a potential approval from the EMA may follow during the first quarter of 2018. Following a potential approval for the treatment indication, we intend to submit a variation to the MAA for the second-line or later maintenance treatment indication, forPhase 1 clinical study, which we anticipate initiating in 2021. In addition to our own planned studies, an academic institution in the U.S. is sponsoring a ~~potential approval during~~separate imaging-only study with FAP-2286 to evaluate FAP expression in multiple tumor types; their IND has been authorized and they expect to initiate their study in the ~~third quarter of 2018.~~near term. We hold U.S. and global rights to FAP-2286, excluding Europe (defined to include Russia, Turkey and Israel), where 3BP retains rights. We also have agreed with 3BP to collaborate on a discovery program directed to up to three additional, undisclosed targets for peptide-targeted radionuclide therapy, to which we would obtain global rights for any resulting product candidates.

Basis of Presentation

All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all ~~adjustments, consisting only of normal recurring~~ adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2019 (“~~2016~~2019 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business.

Table of Contents

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical

~~Table of Contents~~

experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Liquidity

We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of ~~revenues~~revenue from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash.

In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and, if approved by the EMA, in Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our ~~existing~~ cash, cash equivalents, ~~and~~ available-for-sale securities and liquidity available under our financing agreement related to our ATHENA trial will allow us to fund our operating plan through at least the next 12 months.

2. Summary of Significant Accounting Policies

Recently Adopted Accounting Standards

From time to time, the Financial Accounting Standards Board (“FASB”) or other standards-setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through the issuance of an Accounting Standards Update (“ASU”).

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. We adopted ASU 2016-13 as of January 1, 2020. Upon the adoption of ASU 2016-13 on January 1, 2020, we are required to determine whether a decline in the fair value below the amortized cost basis (i.e., impairment) of an available-for-sale debt is security is due to credit-related factors or noncredit-related factors. Any impairment that is not credit related is recognized in accumulated other comprehensive loss, net of applicable taxes. When evaluating an impairment, entities may not use the length of time a security has been in an unrealized loss position as a factor, either by itself or in combination with other factors, to conclude that a credit loss does not exist. We applied this impairment model for available-for-sale debt securities as of January 1, 2020 and 0 impairment was recognized upon adoption. In addition, 0 impairment was recognized for the three and nine months ended September 30, 2020. We recognized a minimal allowance for credit losses related to our accounts receivable at September 30, 2020. The adoption of ASU 2016-13 did not materially impact our consolidated financial statements and disclosures.

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We adopted ASU 2018-02 as of January 1, 2020 and there was no material impact on our consolidated financial statements and related disclosures.

Recently Adopted Accounting Standards

In August 2020, the FASB issued guidance that simplifies an issuer’s accounting for debt and equity instruments. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early application is permitted. We plan to adopt this guidance on January 1, 2022. We will evaluate the impact this guidance may have on our consolidated financial statements and related disclosures as the adoption date approaches.

Table of Contents

Revenue Recognition

~~Product revenue is derived from sales of our product,~~We are currently approved to sell Rubraca in the United ~~States.~~ States and Europe markets. We distribute our product ~~in the U.S.~~ principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently ~~resell~~sell our products to patients and ~~healthcare~~health care providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and ~~other~~ discounts.

Product Revenue

Revenue from product sales are recognized when the performance obligation is satisfied, which is when customers obtain control of our product at a point in time, typically upon delivery. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less.

Reserves for Variable Consideration

Revenues from product sales are ~~recognized when persuasive evidence~~recorded at the net sales price (transaction price), which includes estimates of ~~an arrangement exists, delivery has occurred~~variable consideration for which reserves are established and ~~title of the product and associated risk of loss has passed to the customer, the~~which result from price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Revenue is recorded net of estimatedconcessions that include rebates, chargebacks, discounts, ~~and other deductions as well as~~co-pay assistance, estimated product returns ~~(collectively, “sales deductions”)~~and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customers) or a current liability (if the amount is payable to a party other than a customer). ~~Although~~Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known.

Government Rebates. Rebates include mandated discounts under the Medicaid Drug Rebate Program, the Medicare coverage gap program, the Tricare health program and various European National Health Service, Sick Fund and Clawback programs. Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the Consolidated Balance Sheets. Our rebate estimates are based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. The accrual for rebates is based on the expected utilization from historical data we have accumulated since the Rubraca product launch.

GPO and Payor Rebates. We contract with various private payor organizations and group purchasing organizations (“GPO”), primarily insurance companies, pharmacy benefit managers and hospitals, for the payment of rebates with respect to utilization of our products. We estimate these rebates and record such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.

Chargebacks. Chargebacks are discounts that occur when contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service (“PHS”) organizations and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and ~~specialty pharmacy providers are our customers, we recognize revenue on product sales once~~ the ~~product is resold~~discounted price paid to ~~the patient or healthcare provider by~~ the specialty distributor by the healthcare provider. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates and known sales to specialty distributors adjusted for the estimated utilization by healthcare providers.

Table of Contents

Discounts and Fees. Our payment terms are generally 30 days. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized.

Co-pay assistance. Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. The intent of this program is to reduce the patient’s out of pocket costs. Liabilities for co-pay assistance are based on actual program participation provided by third-party administrators at month end.

Returns. Consistent with industry practice, we generally offer customers a right of return limited only to product that will expire in six months or ~~specialty pharmacy provider, therefore reducing~~product that is six months beyond the ~~significance of estimates made for product returns.~~expiration date. To date, we have had minimal product returns and we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns ~~as we gain~~based on additional historical experience.

Cost of Sales – Product

Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales.Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the manufacturing costs of Rubraca units recognized as revenue during the three and nine months ended September 30, 2017 were expensed prior to the December 19, 2016 FDA approval, and therefore, a minimal amount is included in costs of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories and we expect to use the remaining pre-commercialization inventory for product sales during the fourth quarter of 2017.

~~Table of Contents~~

Cost of Sales – Intangible Asset Amortization

Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca.

~~Inventory~~Accounts Receivable

We provide an allowance for credit losses based on experience and specifically identified risks. Accounts receivable are charged off against the allowance when we determine that recovery is unlikely and we cease collection efforts. At September 30, 2020, we recognized a minimal allowance for credit losses related to our accounts receivable.

Inventory

Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out ~~or FIFO,~~(“FIFO”) basis. Inventories include active pharmaceutical ingredient (“API”), contract manufacturing costs and overhead allocations. We began capitalizing incurred inventory related costs upon the regulatory approval of Rubraca. Prior to the regulatory approval of Rubraca, we incurred costs for the manufacture of the drug that could potentially be available to support the commercial launch of Rubraca and all such costs were recognized as research and development expense.

We ~~periodically~~regularly analyze our inventory levels for excess quantities and obsolescence (expiration), taking into account factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf-life of Rubraca. Rubraca finished goods have a shelf-life of four years from the date of manufacture. We expect to sell the finished goods prior to expiration. The API currently has a shelf-life of four years from the date of manufacture but can be retested at an immaterial cost with no expected reduction in potency, thereby extending its shelf-life as needed. We expect to consume substantially all of the API over a period of approximately seven years based on our long-range sales projections of Rubraca.

We write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales ~~requirements as cost of product revenues.~~requirements. Expired inventory would be disposed of and the related costs would be written off as cost of product ~~revenues.~~ revenue. Inventories that are not expected to be consumed within 12 months following the balance sheet date are classified as long-term inventories. Long-term inventories primarily consist of API.

~~The active pharmaceutical ingredient (“API”) in Rubraca~~12

Table of Contents

API is currently produced by ~~a single supplier.~~Lonza. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory. In addition, we currently manufacture Rubraca finished goods with a single third-party manufacturer. The disruption or termination of the supply of API or the disruption or termination of the manufacturing of our commercial products could have a material adverse effect on our business, financial position and results of operations. API that is written off due to damage and certain costs related to our dedicated production train at Lonza are included in Other Operating Expenses in the Consolidated Statements of Operations and Comprehensive Loss.

Inventory used in clinical trials is expensed as research and development expense when it has been identified for such use.

Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies of the Notes to the Consolidated Financial Statements included in our ~~2016~~2019 Form 10-K.

~~Recently Issued Accounting Standards~~

From time to time, the Financial Accounting Standards Board (“FASB”) or other standards setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through issuance of an Accounting Standards Update (“ASU”).

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We expect to apply the new standard using the modified retrospective method upon its adoption date on January 1, 2018.

We have begun a comprehensive scoping process to identify and disaggregate all revenue streams that may be impacted by the adoption of ASC 606. To date, we have examined our revenue recognition policy specific to revenue streams from representative contracts governing product sales from Rubraca and have come to preliminary conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. We have reviewed a representative sample of contracts, including our collaboration agreements with Servier and ~~Bristol-Myers Squibb discussed in Note 12,~~ ~~License Agreements~~, and determined the potential impact to our accounting policies, financial controls and operations. Our preliminary conclusions include recognizing revenue on product sales once the product is sold to the specialty distributor and specialty pharmacy providers. We have not yet completed our final review of the impact of this guidance including the new disclosure requirements, as we are continuing to evaluate the impacts of adoption. We continue to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact our preliminary conclusions.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into

~~Table of Contents~~

after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.

In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” which clarifies the definition of a business in ASC 805. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. Currently, there is no impact to our consolidated financial statements and related disclosures, but we will adopt on January 1, 2018 for any business combinations and will consider adopting early for any acquisitions prior to January 1, 2018.

In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting”, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which we would be required to apply modification accounting under ASC 718. Specifically, we would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is effective for annual reporting periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures should we have a modification to our share-based payment awards in the future.

3. Financial Instruments and Fair Value Measurements

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The three levels of inputs that may be used to measure fair value include:

Level 1:	Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market ~~investments.~~investments and U.S. treasury securities. We do not have Level 1 liabilities.

Level 2:	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

Level 3:	Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets or liabilities that are measured at fair value on a recurring basis.

The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
September 30, 2017

									Balance		Level 1		Level 2		Level 3
September 30, 2020
Assets:
Money market	$	590,037	$	590,037	$	—	$	—	$	147,918	$	147,918	$	0	$	0
U.S. treasury securities		16,499		—		16,499		—		—		—		—		0
Total assets at fair value	$	606,536	$	590,037	$	16,499	$	—	$	147,918	$	147,918	$	—	$	0
December 31, 2016
December 31, 2019
Assets:
Money market	$	202,361	$	202,361	$	—	$	—	$	61,882	$	61,882	$	0	$	0
U.S. treasury securities		49,997		—		49,997		—		189,736		54,910		134,826		0
Total assets at fair value	$	252,358	$	202,361	$	49,997	$	—	$	251,618	$	116,792	$	134,826	$	0

There were no0 liabilities that were measured at fair value on a recurring basis as of September 30, 2020. There were 0 transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during ~~the~~ three and nine months ended September 30, ~~2017.~~2020.

~~Table of Contents~~

Financial instruments not recorded at fair value include our convertible senior notes. At September 30, ~~2017,~~2020, the carrying amount of the ~~convertible senior notes~~2021 Notes was ~~$282.1~~$64.1 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was ~~$444.2~~$59.4 million. At September 30, 2020, the carrying amount of the 2024 Notes was $147.2 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $145.9 million. At September 30, 2020, the carrying amount of the 2025 Notes was $293.9 million, which

Table of Contents

represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $204.2 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of ~~the Notes,~~these notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 9, ~~Convertible Senior Notes~~10, Long-term Debt for discussion of the convertible senior notes. The carrying amounts of accounts payable and accrued expenses approximate their fair value due to their short-term maturities.

4. Available-for-Sale Securities

We did not have available-for-sale securities as of September 30, 2020.

As of ~~September 30, 2017,~~December 31, 2019, available-for-sale securities consisted of the following (in thousands):

Gross

Gross

Aggregate

Amortized

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

U.S. treasury securities

$
16,498

$
1

$
—

$
16,499


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	134,826	$	0	$	—	$	134,826

~~As of December 31, 2016, available-for-sale securities consisted of the following (in thousands):~~

Gross

Gross

Aggregate

Amortized

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

U.S. treasury securities

$
50,004

$
—

$
(7)

$
49,997

~~As of September 30, 2017, there were no available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months.~~

~~As of September 30, 2017, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):~~

Amortized

Fair

Cost

Value

Due in one year or less

$
16,498

$
16,499

Due in one year to two years

—

—

Total

$
16,498

$
16,499

5. Inventories

The following table presents current and long-term inventories as of September 30, ~~2017~~2020 and December 31, ~~2016:~~2019:

September 30,

December 31,

2017

2016
Work in process

3,482

—
Finished goods

1,863

—
Total inventories

5,345

—


	September 30,		December 31,
	2020		2019
Work-in-process	$	101,711	$	104,139
Finished goods, net		32,363		20,433
Total inventories	$	134,074	$	124,572

~~Some of the costs related to our finished goods on-hand as of September 30, 2017 were expensed as incurred prior to the commercialization of Rubraca on December 19, 2016.~~

At September 30, ~~2017, deposit on~~2020, we had $24.6 million of current inventory ~~on the Consolidated Balance Sheets is a cash deposit~~and $109.4 million of ~~$31.8 million made to a manufacturer for the purchase of inventory which we expect to be converted to finished goods within the next twelve months.~~long-term inventory.

~~Table of Contents~~

6. Other Current Assets

Other current assets were comprised of the following (in thousands):


	September 30,		December 31,
	2017		2016
Receivable from partners	$	64	$	2,882

					September 30,		December 31,
					2020		2019
Prepaid insurance		604		1,234	$	1,338	$	505
Prepaid IT						1,210		698
Prepaid variable considerations						1,526		550
Prepaid expenses - other		3,811		2,109		2,692		2,821
Value-added tax ("VAT") receivable						8,054		11,920
Receivable - other		1,274		364		1,342		2,176
Other		158		90		106		177
Total	$	5,911	$	6,679	$	16,268	$	18,847

7. Intangible Assets and Goodwill

Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):


	September 30,		December 31,
	2020		2019
Intangible asset - milestones	$	79,850	$	71,850
Accumulated amortization		(12,764)		(8,930)
Total intangible asset, net	$	67,086	$	62,920

September 30,

December 31,

2017

2016

Intangible asset - milestones

$
21,100

$
21,100

Accumulated amortization

(1,168)

(53)

Total intangible asset, net

$
19,932

$
21,047

Table of Contents

The increase in our intangible asset – milestones since December 31, 2019 is due to an $8.0 million milestone payment to Pfizer related to the May 2020 FDA approval. See Note 13, License Agreements for further discussion of this approval.

The estimated useful lives of these intangible assets are based on the estimated remaining patent life of Rubraca and extend through ~~2031.~~2031 in Europe and 2035 in the U.S.

We recorded amortization expense of ~~$0.4~~$1.3 million and ~~$1.2~~$3.8 million related to capitalized milestone payments during the three and nine months ended September 30, ~~2017, respectively,~~2020, respectively. We recorded amortization expense of $1.2 million and $3.5 million related to capitalized milestone payments during the three and nine months ended September 30, 2019, respectively. Amortization expense is included in cost of sales – intangible asset amortization on the Consolidated Statements of Operations and Comprehensive Loss. ~~There was no amortization expense during the three and nine months ended September 30, 2016.~~

Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):

2017 (remaining)

$
372

2018

1,486

2019

1,486

2020

1,486

2021

1,486

Thereafter

13,616

$
19,932


2020 (remaining three months)	$	1,343
2021		5,371
2022		5,371
2023		5,371
2024		5,371
Thereafter		44,259
	$	67,086

~~The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):~~

Balance at December 31, 2016

$
57,192

Change in foreign currency gains and losses

7,061

Balance at September 30, 2017

$
64,253

~~Table of Contents~~

8. Other Accrued Expenses

Other accrued expenses were comprised of the following (in thousands):


	September 30,		December 31,
	2017		2016

					September 30,		December 31,
					2020		2019
Accrued personnel costs	$	9,770	$	15,850	$	15,090	$	16,915
Accrued interest payable		299		2,096
Accrued interest payable for convertible senior notes						2,730		5,903
Income tax payable		74		556		1,063		3,505
Accrued corporate legal fees and professional services		612		589		441		310
Accrued royalties		2,932		—		5,907		6,038
Accrued sales deductions		1,254		—
Accrued variable considerations						8,969		5,748
Purchase of API received not yet invoiced						41		—
Accrued expenses - other		2,526		396		6,163		3,809
Total	$	17,467	$	19,487	$	40,404	$	42,228

9. ~~Convertible Senior~~Lease

At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. We elected not to recognize on the balance sheet leases with terms of one year or less. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

The components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, maintenance, consumables, etc.) and non-components (e.g. property

Table of Contents

taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on fair values assigned to the lease components and non-lease components.

Our facilities operating leases have lease components, non-lease components and non-components, which we have separated because the non-lease components and non-components have variable lease payments and are excluded from the measurement of the lease liabilities. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis to the statements of operations.

We lease all of our office facilities in the U.S. and Europe. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Most leases include one or more options to renew. The exercise of lease renewal options is at our sole discretion. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

We have a finance lease for certain equipment at the dedicated production train at Lonza, our non-exclusive manufacturer of the Rubraca API.

The components of lease expense and related cash flows were as follows (in thousands):


	Three months ended September 30,		Three months ended September 30,
	2020		2019
Lease cost
Finance lease cost:
Amortization of right-of-use assets	$	474	$	356
Interest on lease liabilities		201		174
Operating lease cost		1,275		667
Short-term lease cost		88		80
Variable lease cost		503		379
Total lease cost	$	2,541	$	1,656

Operating cash flows from finance leases	$	201	$	174
Operating cash flows from operating leases	$	1,275	$	667
Financing cash flows from finance leases	$	371	$	260


		Nine months ended September 30,		Nine months ended September 30,
		2020		2019
Lease cost
Finance lease cost:
Amortization of right-of-use assets		$	1,421	$	1,068
Interest on lease liabilities			624		537
Operating lease cost			3,400		2,811
Short-term lease cost			310		177
Variable lease cost			1,573		1,749
Total lease cost		$	7,328	$	6,342

Operating cash flows from finance leases	��	$	624	$	537
Operating cash flows from operating leases		$	3,400	$	2,811
Financing cash flows from finance leases		$	1,092	$	765

The weighted-average remaining lease term and weighted-average discount rate were as follows:


	September 30, 2020		September 30, 2019
Weighted-average remaining lease term (years)
Operating leases		6.8		7.2
Finance leases		5.3		6.3
Weighted-average discount rate

Table of Contents

Operating leases			8%			8%
Finance leases			8%			8%

Future minimum commitments due under these lease agreements as of September 30, 2020 are as follows (in thousands):


	Operating Leases		Finance Leases		Total
2020 (remaining three months)		1,381		572		1,953
2021		5,668		2,287		7,955
2022		5,204		2,287		7,491
2023		4,818		2,287		7,105
2024		4,827		2,287		7,114
Thereafter		14,758		2,287		17,045
Present value adjustment		(8,807)		(2,229)		(11,036)
Present value of lease payments	$	27,849	$	9,778	$	37,627

10. Long-term Debt

The following is a summary of our convertible senior notes at September 30, 2020 and December 31, 2019 (principal amount in thousands):


	Principal Amount		Principal Amount
	September 30, 2020		December 31, 2019		Interest Rate	Due Date
2021 Notes	$	64,418	$	97,188	2.50%	September 15, 2021
2024 Notes		150,624		263,000	4.50%	August 1, 2024
2025 Notes		300,000		300,000	1.25%	May 1, 2025
Total	$	515,042	$	660,188

2021 Notes

OnIn September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the ~~“Notes”~~“2021 Notes”) resulting in net proceeds of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

The 2021 Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The 2021 Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year. The 2021 Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.

Holders may convert all or any portion of the 2021 Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of 2021 Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the ~~indenture, but will not be adjusted for any accrued and unpaid interest.~~indenture. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the 2021 Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

On or after September 15, 2018, we may redeem the 2021 Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than ~~two~~2 trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2021 Notes.

Table of Contents

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the 2021 Notes, holders may require us to repurchase for cash all or any portion of the 2021 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2021 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The 2021 Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2021 Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

In connection with the issuance of the 2021 Notes, we incurred $9.2 million of debt issuance ~~costs.~~costs, of which $2.0 million of unamortized debt issuance costs were derecognized in connection with the repurchase of the 2021 Notes. The remaining debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the 2021 Notes using the effective interest method. We determined the expected

~~Table of Contents~~

life of the debt was equal to the seven-year term of the 2021 Notes.

In August 2019, we entered into privately negotiated transactions with a limited number of holders to repurchase $190.3 million aggregate principal amount of our outstanding 2021 Notes for an aggregate repurchase price of $171.8 million, including accrued interest. This repurchase resulted in the recognition of $18.5 million gain on extinguishment of debt.

2024 Notes

In August 2019, we completed a private placement to qualified institutional buyers of $263.0 million aggregate principal amount of 4.50% convertible senior notes due 2024 (the “2024 Notes”) resulting in net proceeds of $254.9 million, after deducting underwriting discounts and commissions and offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

The 2024 Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The 2024 Notes are senior unsecured obligations and bear interest at a rate of 4.50% per year, payable semi-annually in arrears on February 1 and August 1 of each year. The 2024 Notes will mature on August 1, 2024, unless earlier repurchased or converted.

Holders may convert all or any portion of the 2024 Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 137.2213 shares per $1,000 in principal amount of 2024 Notes, equivalent to a conversion price of approximately $7.29 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the 2024 Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

We will not have the right to redeem the 2024 Notes prior to their maturity. If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the 2024 Notes, holders may require us to repurchase for cash all or any portion of the 2024 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. No sinking fund is provided for the 2024 Notes.

The 2024 Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes; equal in right of payment to all of our liabilities that are not so subordinated, including the 2021 Notes and 2025 Notes; effectively junior in right of payment to any secured indebtedness to the extent of the value

Table of Contents

of the assets securing such indebtedness, including our borrowing under the TPG financing agreement; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

In connection with the issuance of the 2024 Notes, we incurred $8.0 million of debt issuance costs. The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the 2024 Notes using the effective interest method. We determined the expected life of the debt was equal to the five-year term of the 2024 Notes.

In January 2020, we completed a registered direct offering of an aggregate 17,777,679 shares of our common stock at a price of $9.25 per share. We used the proceeds of the share offering to repurchase an aggregate of $123.4 million principal amount of 2024 Notes in privately negotiated transactions. In addition, we paid customary fees and expenses in connection with the transactions. As a result of this transaction, $3.6 million of unamortized debt issuance costs were derecognized and we recognized a $7.8 million loss on the transactions.

In April 2020, we completed the Exchange Transaction discussed in the 2021 Notes section above.

The Additional 2024 Notes issued in the Exchange Transaction were issued as Additional Notes under that certain Indenture, dated as of August 13, 2019 (the “Indenture”), by and between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, and have substantially identical terms to our currently outstanding 2024 Notes, except that the Additional 2024 Notes will accrue interest from February 1, 2020 and the initial interest payment date on the Additional 2024 Notes was August 1, 2020. The Holder paid to the Company accrued interest on the Additional 2024 Notes from February 1, 2020 to and including April 20, 2020. The Additional 2024 Notes will be treated as a single series of securities with the currently outstanding 2024 Notes.

In April and May 2020, approximately $24.3 million in principal amount of 2024 Notes were converted into 3,331,870 shares of our common stock at the conversion rate of 137.2213 shares per $1,000 in principal amount of 2024 Notes.

Subsequent Event

In November 2020, we entered into a privately negotiated exchange and purchase agreement with a holder of our 2024 Notes. Pursuant to the agreement, in exchange for approximately $64.8 aggregate principal amount of 2024 Notes held by the holder, we agreed to issue to the holder a number shares of our common stock (the “Exchanged Shares”) utilizing an exchange ratio that is based in part on the daily volume-weighted average prices (“VWAPs”) per share of our common stock during a 7-day pricing period following execution of the agreement.

In addition, pursuant to the agreement, we also agreed to sell to the holder $50.0 million aggregate principal amount of a new series of 4.50% Convertible Senior Notes due 2024 (the “New 2024 Notes”) at a purchase price of $1,000 per $1,000 principal amount thereof. Also, we granted the holder a 13-day option to purchase up to an additional $20.0 million aggregate principal amount of New 2024 Notes on the same terms and conditions.

The number of Exchanged Shares will be calculated utilizing an exchange ratio that is based in part on the average VWAPs of our common stock (subject to a floor) during a 7-day pricing period beginning on November 5, 2020 and ending on, and including, November 13, 2020. Assuming such average VWAP is $5.67 per share, which is the last reported sale price of our common stock on November 4, 2020, 13,038,683 Exchanged Shares would be issuable pursuant to the debt exchange transaction. However, in the event that our stock price declines during the pricing period, we will be required to issue more shares, but in no event more than 15,696,240 Exchanged Shares are issuable pursuant to the debt exchange transaction.

2025 Notes

In April 2018, we completed an underwritten public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025 (the “2025 Notes”) resulting in net proceeds of $290.9 million, after deducting underwriting discounts and commissions and offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

Table of Contents

The 2025 Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the terms of that certain first supplemental indenture thereto. The 2025 Notes are senior unsecured obligations and bear interest at a rate of 1.25% per year, payable semi-annually in arrears on May 1 and November 1 of each year. The 2025 Notes will mature on May 1, 2025, unless earlier converted, redeemed or repurchased.

Holders may convert all or any portion of the 2025 Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 13.1278 shares per $1,000 in principal amount of 2025 Notes, equivalent to a conversion price of approximately $76.17 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the 2025 Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

On or after May 2, 2022, we may redeem the 2025 Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than 2 trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the 2025 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2025 Notes.

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the 2025 Notes, holders may require us to repurchase for cash all or any portion of the 2025 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The 2025 Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2025 Notes; equal in right of payment to all of our liabilities that are not so subordinated, including the 2021 Notes; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

In connection with the issuance of the 2025 Notes, we incurred $9.1 million of debt issuance costs. The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the 2025 Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the 2025 Notes.

As of September 30, ~~2017~~2020 and December 31, ~~2016,~~2019, the balance of unamortized debt issuance costs related to the 2021 Notes, 2024 Notes and 2025 Notes was $9.8 million and $15.4 million, respectively.

TPG Financing Agreement

On May 1, 2019, we entered into a financing agreement (the “Financing Agreement”) with certain affiliates of TPG Sixth Street Partners, LLC (“TPG”) in which we plan to borrow from TPG amounts required to reimburse our actual costs and expenses incurred during each fiscal quarter (limited to agreed budgeted amounts), as such expenses are incurred, related to the ATHENA clinical trial, in an aggregate amount of up to $175 million (the amount actually borrowed, the “Borrowed Amount”). ATHENA is our largest clinical trial, with a planned target enrollment of 1,000 patients across more than 270 sites in at least 25 countries. The Clovis-sponsored phase 3 ATHENA study in advanced ovarian cancer is the first-line maintenance treatment setting evaluating Rubraca plus nivolumab (PD-1 inhibitor), Rubraca, nivolumab and a placebo in newly-diagnosed patients who have completed platinum-based chemotherapy. This study initiated in the second quarter of 2018 and we completed target enrollment during the second quarter of 2020.

We incur borrowings under the Financing Agreement on a quarterly basis, beginning with such expenses incurred during the quarter ended March 31, 2019 and ending generally on the earliest to occur of (i) the termination of the ATHENA Trial, (ii) the date of completion of all activities under the ATHENA Trial Clinical Study Protocol, (iii) the date on which we pay the Discharge Amount (as defined in the Financing Agreement), (iv) the date of the occurrence of a change of control of us (or a sale of all or substantially all of our assets related to Rubraca) or our receipt of notice of

Table of Contents

certain breaches by us of our obligations under material in-license agreements related to Rubraca and (v) September 30, 2022.

We are obligated to repay on a quarterly basis, beginning on the earliest to occur of (i) the termination of the ATHENA Trial, (ii) the approval by the FDA of an update to the label portion of the Rubraca new drug application (“NDA”) to include in such label the treatment of an indication resulting from the ATHENA Trial, (iii) the date on which we determine that the results of the ATHENA Trial are insufficient to achieve such an expansion of the Rubraca label to cover an indication based on the ATHENA Trial and (iv) September 30, 2022 (the “Repayment Start Date”).

●

9.75% (which rate may be increased incrementally up to approximately 10.25% in the event the Borrowed Amount exceeds $166.5 million) of the direct Rubraca net sales recorded by us and our subsidiaries worldwide and our future out-licensees in the United States, if any, during such quarter;

●

19.5% of any royalty payments received by us and our subsidiaries during such quarter based on the sales of Rubraca by our future out-licensees outside the United States, if any; and

●

19.5% of any other amounts received by us and our subsidiaries in connection with any other commercialization arrangement for Rubraca, including any upfront and milestone payments and proceeds of infringement claims (which payments are not subject to the caps described below).

Quarterly payments are capped at $8.5 million, unless the label portion of the Rubraca NDA is expanded by the FDA to include such label the treatment of an indication resulting from the ATHENA Trial, in which case the quarterly payment is capped at $13.5 million. In the event the aggregate Borrowed Amount exceeds $166.5 million, such quarterly limits will be incrementally increased to a maximum of approximately $8.94 million and $14.19 million, respectively. The maximum amount required to be repaid under the agreement is 2 times the aggregate Borrowed Amount, which may be $350 million in the event we borrow the full $175 million under the Financing Agreement.

In the event we have not made payments on or before December 30, 2025 equal to at least the Borrowed Amount, we are required to make a lump sum payment in an amount equal to such Borrowed Amount less the aggregate of all prior quarterly payments described above. All other payments are contingent on the performance of Rubraca. There is no final maturity date on the Financing Agreement.

Our obligations under the Financing Agreement are secured under a Pledge and Security agreement by a first priority security interest in all of our assets related to Rubraca, including intellectual property rights and a pledge of the equity of our wholly owned subsidiaries, Clovis Oncology UK Limited and Clovis Oncology Ireland Limited. In addition, the obligations are guaranteed by Clovis Oncology UK Limited and Clovis Oncology Ireland Limited, secured by a first priority security interest in all the assets of those subsidiaries.

Pursuant to the Financing Agreement, we have agreed to certain limitations on our operations, including limitations on making certain restricted junior payments, including payment of dividends, limitation on liens and certain limitations on the ability of our non-guarantor subsidiaries to own certain assets related to Rubraca and to incur indebtedness.

We may terminate the Financing Agreement at any time by paying the lenders an amount (the “Discharge Amount”) equal to the sum of (a) (A) the greater of (x) the Borrowed Amount plus (i) if such date is during calendar year 2019, $35 million or (ii) if such date is during calendar year 2020 or thereafter, $50 million and (y) (i) if such date is prior to the Repayment Start Date, 1.75 times the Borrowed Amount or (ii) if such date is after the Repayment Start Date, 2.00 times the Borrowed Amount minus (B) the aggregate amount of all quarterly payments previously paid to the lenders plus (b) all other obligations which have accrued but which have not been paid under the loan documents, including expense reimbursement.

In the event of (i) a change of control of us, we must pay the Discharge Amount to the lenders and (ii) an event of default under the Financing Agreement (which includes, among other events, breaches or defaults under or terminations of our material in-license agreements related to Rubraca and defaults under our other material indebtedness), the lenders have the right to declare the Discharge Amount to be immediately due and payable.

Table of Contents

For the nine months ended September 30, 2020, we recorded $92.1 million as a long-term liability on the Consolidated Balance Sheets and future quarterly draws will be recorded as a long-term liability on the Consolidated Balance Sheets. In connection with the transaction, we incurred $1.8 million of debt issuance costs. The debt issuance costs are presented as a deduction from the TPG financing liability on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the Financing Agreement using the straight-line method. As of September 30, 2020, the balance of unamortized debt issuance costs was ~~$5.4 million~~$1.5 million.

For the nine months ended September 30, 2020, we used an effective interest rate of 14.5%. For subsequent periods, we will use the prospective method whereby a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and ~~$6.4 million, respectively~~.it will be used to recognize interest expense for the remaining periods. Under this method, the effective interest rate is not constant, and any change in expected cash flows is recognized prospectively as an adjustment to the effective yield.

The following table sets forth total interest expense recognized during the three and nine months ended September 30, ~~2017~~2020 and ~~2016~~2019 (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2017		2016		2017		2016
Contractual interest expense	$	1,797	$	1,797	$	5,391	$	5,390
Accretion of interest on milestone liability		500		—		1,449		—

									Three months ended September 30,				Nine months ended September 30,��
									2020		2019		2020		2019
Interest on convertible notes									$	3,024	$	3,708	$	9,018	$	9,176
Amortization of debt issuance costs		321		311		956		928		644		746		2,068		2,070
Debt issuance cost derecognized related to convertible debt transactions										—		—		4,344		—
Interest on finance lease										201		174		624		537
Interest on borrowings under ATHENA financing agreement										2,962		625		7,017		824
Other interest										28		25		89		77
Total interest expense	$	2,618	$	2,108	$	7,796	$	6,318	$	6,859	$	5,278	$	23,160	$	12,684

~~10.~~11. Stockholders’ Equity

Common Stock

In ~~January 2017,~~May 2020, we sold ~~5,750,000~~11,090,000 shares of our common stock in a public offering at ~~$41.00~~$8.05 per share. The net proceeds from the offering were ~~$221.2~~$82.8 million, after deducting underwriting discounts and commissions and offering expenses.In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses.

The holders of common stock are entitled to ~~one~~1 vote per share on all matters to be voted upon by our stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors.

Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities.

Table of Contents

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended September 30, ~~2017~~2020 and ~~2016,~~2019, as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2017		2016		2017		2016		2017		2016

													Foreign Currency				Unrealized				Total Accumulated
													Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
													2020		2019		2020		2019		2020		2019
Balance at July 1,	$	(44,155)	$	(44,945)	$	(151)	$	(105)	$	(44,306)	$	(45,050)	$	(44,774)	$	(44,466)	$	(139)	$	(22)	$	(44,913)	$	(44,488)
Other comprehensive income (loss)		2,510		115		15		(29)		2,525		86		254		(143)		—		(68)		254		(211)
Total before tax		(41,645)		(44,830)		(136)		(134)		(41,781)		(44,964)		(44,520)		(44,609)		(139)		(90)		(44,659)		(44,699)
Tax effect		(915)		(57)		(5)		11		(920)		(46)		0		0		0		—		0		0
Balance at September 30,	$	(42,560)	$	(44,887)	$	(141)	$	(123)	$	(42,701)	$	(45,010)	$	(44,520)	$	(44,609)	$	(139)	$	(90)	$	(44,659)	$	(44,699)

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the nine months ended September 30, ~~2017~~2020 and ~~2016~~2019, as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2017		2016		2017		2016		2017		2016

													Foreign Currency				Unrealized				Total Accumulated
													Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
													2020		2019		2020		2019		2020		2019
Balance at January 1,	$	(47,434)	$	(47,077)	$	(146)	$	(383)	$	(47,580)	$	(47,460)	$	(44,732)	$	(44,460)	$	(133)	$	(174)	$	(44,865)	$	(44,634)
Other comprehensive income (loss)		7,695		3,526		8		412		7,703		3,938
Other comprehensive (loss) income														212		(149)		(6)		84		206		(65)
Total before tax		(39,739)		(43,551)		(138)		29		(39,877)		(43,522)		(44,520)		(44,609)		(139)		(90)		(44,659)		(44,699)
Tax effect		(2,821)		(1,336)		(3)		(152)		(2,824)		(1,488)		—		—		—		—		—		—
Balance at September 30,	$	(42,560)	$	(44,887)	$	(141)	$	(123)	$	(42,701)	$	(45,010)	$	(44,520)	$	(44,609)	$	(139)	$	(90)	$	(44,659)	$	(44,699)

~~Table of Contents~~

~~The period change in each of the periods presented was primarily due to the currency translation of the goodwill and deferred income taxes associated with the acquisition of EOS in November 2013.~~ There were no0 reclassifications out of accumulated other comprehensive loss in each of the three and nine months ended September 30, ~~2017~~2020 and ~~2016.~~2019.

~~11.~~12. Share-Based Compensation

Share-based compensation expense for all ~~equity based~~equity-based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and nine months ended September 30, ~~2017~~2020 and ~~2016~~2019 was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2017		2016		2017		2016

									Three months ended September 30,				Nine months ended September 30,
									2020		2019		2020		2019
Research and development	$	5,636	$	7,039	$	14,628	$	20,962	$	6,284	$	6,561	$	19,845	$	19,805
Selling, general and administrative		7,001		2,164		17,573		8,782		6,207		7,418		18,920		21,943
Total share-based compensation expense	$	12,637	$	9,203	$	32,201	$	29,744	$	12,491	$	13,979	$	38,765	$	41,748

We did not recognize a tax benefit related to share-based compensation expense during the three and nine months ended September 30, ~~2017~~2020 and ~~2016, respectively,~~2019, as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of September 30, ~~2017.~~2020.

Table of Contents

Stock Options

The following table summarizes the activity relating to our options to purchase common stock for the nine months ended September 30, ~~2017:~~2020:

Weighted


Weighted

Average

Aggregate

Average

Remaining

Intrinsic

Number of

Exercise

Contractual

Value

Options

Price

Term (Years)

(Thousands)

Outstanding at December 31, 2016

5,520,482

$
42.00





Granted

895,200





Exercised

(439,449)





Forfeited

(217,771)





Outstanding at September 30, 2017

5,758,462

$
46.32

7.3

$
211,301

Vested and expected to vest at September 30, 2017

5,436,766

$
46.10

7.2

$
200,599

Vested and exercisable at September 30, 2017

3,280,881

$
44.09

6.2

$
127,295


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value
	Options	Price		Term (Years)	(Thousands)
Outstanding at December 31, 2019	6,287,025	$	42.24
Granted	907,592		7.56
Exercised	(24,153)		3.08
Forfeited	(487,171)		48.40
Outstanding at September 30, 2020	6,683,293	$	37.22	5.9	$	502
Vested and expected to vest at September 30, 2020	6,532,307	$	37.66	5.8	$	490
Vested and exercisable at September 30, 2020	4,956,674	$	43.65	4.9	$	274

The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of ~~$82.40~~$5.83 as of September ~~29, 2017,~~30, 2020, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.

The following table summarizes information about our stock options as of and for the three and nine months ended September 30, ~~2017~~2020 and ~~2016~~2019 (in thousands, except per share amounts):


	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Weighted-average grant date fair value per share	$	4.88	$	4.40	$	5.83	$	14.40
Intrinsic value of options exercised	$	—	$	560	$	91	$	1,523
Cash received from stock option exercises	$	—	$	44	$	74	$	1,360

Three months ended September 30,

Nine months ended September 30,


2017

2016

2017

2016

Weighted-average grant date fair value per share

$
60.81

$
17.09

$
48.39

$
16.07

Intrinsic value of options exercised

$
3,400

$
930,417

$
17,684

$
1,555,342

Cash received from stock option exercises

$
2,149

$
687,332

$
13,262

$
1,094,855

~~Table of Contents~~

As of September 30, ~~2017,~~2020, the unrecognized share-based compensation expense related to unvested options, adjusted for expected forfeitures, was ~~$77.5~~$22.9 million and the estimated weighted-average remaining vesting period was ~~2.5~~1.6 years.

Restricted Stock

During 2016, we issued restricted stock units (“RSUs”) to certain employees under the 2011 Stock Incentive Plan. The RSUs vest either (i) over two years, with 50% vesting one year from the date of grant and the remaining 50% vesting two years from the date of grant or (ii) over four years, with 25% vesting one year from the date of grant and the remaining 75% vesting ratably each subsequent quarter over the following three years, as defined in the grant agreement. Vested RSUs are payable in shares of our common stock at the end of the vesting period. RSUs are measured based on the fair value of the underlying stock on the grant date. The minimum statutory tax on the value of common stock shares issued to employees upon vesting are paid by us through the sale of registered shares of our common stock.

The following table summarizes the activity relating to our unvested ~~RSUs~~restricted stock units (“RSUs”) for the nine months ended September 30, ~~2017:~~2020:

Weighted

Average

Number of

Grant Date

Units

Fair Value

Unvested at December 31, 2016

562,458

$
24.70

Granted

244,484

64.70

Vested

(136,795)

21.45

Forfeited

(33,807)

26.08

Unvested as of September 30, 2017

636,340

$
40.69

Expected to vest after September 30, 2017

545,549

$
40.35



		Weighted
		Average
	Number of	Grant Date
	Units	Fair Value
Unvested at December 31, 2019	2,171,347	$	28.37
Granted	2,407,678		8.26
Vested	(888,146)		28.61
Forfeited	(389,266)		17.94
Unvested at September 30, 2020	3,301,613	$	14.86
Expected to vest after September 30, 2020	3,173,818	$	14.48

As of September 30, ~~2017,~~2020, the unrecognized share-based compensation expense related to unvested RSUs, adjusted for expected forfeitures, was ~~$18.9~~$41.2 million and the estimated weighted-average remaining vesting period was ~~3.2~~2.2 years.

~~12.~~24

Table of Contents

13. License Agreements

Rucaparib

In June 2011, we entered into a ~~worldwide~~ license agreement with Pfizer, Inc. (“Pfizer”) to obtain the exclusive global rights to develop and commercialize ~~rucaparib, a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), used for the treatment of selected solid tumors.~~Rubraca. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of ~~rucaparib, discussed below,~~Rubraca, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense.

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1^st Indication in US and (ii) EMA approval of an MAA for 1^st Indication in the EU, to a date that is 18 months after the date of achievement of such milestones. ~~In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones.~~

On December 19, 2016, ~~the~~Rubraca received its initial FDA ~~approved Rubraca~~(rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. The FDAapproval. This approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was ~~made~~paid in the first quarter of ~~2017. The~~2017. This FDA approval also resulted in ~~the~~an obligation to pay a $20.0 million milestone payment, for which we ~~have~~ exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. We paid the $23.0 million milestone payment in June 2018.

In April 2018, Rubraca received a second FDA approval. This approval resulted in an obligation to pay a $15.0 million milestone payment, which we paid in April 2018.

In May 2018, Rubraca received its initial European Commission marketing authorization. This approval resulted in an obligation to pay a $20.0 million milestone payment, which we paid in June 2018.

In January 2019, Rubraca received a second European Commission approval. This approval resulted in an obligation to pay a $15.0 million milestone payment, which we paid in February 2019.

In June 2019, we paid a $0.75 million milestone payment due to the launch of Rubraca as maintenance therapy in Germany in March 2019.

In May 2020, Rubraca received a third FDA approval for Rubraca as a monotherapy treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer. This approval resulted in an obligation to pay an $8.0 million milestone payment, which we paid in June 2020.

These milestone payments were recognized as intangible assets and ~~will be~~are amortized over the estimated remaining useful life of Rubraca.

~~Table of Contents~~

We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize ~~rucaparib~~Rubraca and we are responsible for all ~~remaining~~ongoing development and commercialization costs for ~~rucaparib.~~Rubraca. We are required to make regulatory milestone payments to Pfizer of up to an additional ~~$69.75~~$8.0 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for ~~rucaparib~~Rubraca are met, ~~the majority of~~ which relate to annual sales targets of ~~$500.0~~$250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on ~~our~~ net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize ~~rucaparib.~~Rubraca.

The license agreement with Pfizer will remain in effect until the expiration of all of our royalty and sublicense revenue obligations to Pfizer, determined on a product-by-product and country-by-country basis, unless we elect to terminate the license agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Pfizer can terminate the agreement, resulting in a loss of our rights to Rubraca and an obligation to assign or license to Pfizer any intellectual property rights or other rights we may have in Rubraca, including our regulatory filings, regulatory approvals, patents and trademarks for Rubraca.

Table of Contents

In April 2012, we entered into a license agreement with AstraZeneca ~~UK Limited~~ to acquire exclusive rights associated with ~~rucaparib~~Rubraca under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of ~~rucaparib~~Rubraca for the uses claimed by these patents. ~~The~~AstraZeneca also receives royalties on net sales of Rubraca.

Lucitanib

On November 19, 2013, we acquired all of the issued and outstanding capital stock of EOS pursuant to the terms set forth in that certain Stock Purchase Agreement, dated as of November 19, 2013 (the “Stock Purchase Agreement”), by and among the Company, EOS, its shareholders (the “Sellers”) and Sofinnova Capital V FCPR, acting in its capacity as the Sellers’ representative. Following the acquisition, EOS became a wholly-owned subsidiary of the Company. Under the terms of the Stock Purchase Agreement, in addition to the initial purchase price paid at the time of the closing of the acquisition and other license fees due to Advenchen described below, we will also be obligated to pay to the Sellers a milestone payment of $65.0 million upon obtaining the first NDA approval from the FDA ~~approval~~with respect to lucitanib.

In October 2008, Ethical Oncology Science, S.p.A. (“EOS”) (now known as Clovis Oncology Italy S.r.l.) entered into an exclusive license agreement with Advenchen Laboratories LLC (“Advenchen”) to develop and commercialize lucitanib on a global basis, excluding China.

We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of ~~rucaparib~~lucitanib, based on ~~December 19, 2016 resulted in a $0.35 million milestone obligation~~the volume of annual net sales achieved. In addition, after giving effect to ~~AstraZeneca as required by~~the first and second amendments to the license agreement, ~~which was paid~~we are required to pay to Advenchen 25% of any consideration, excluding royalties, we receive from sublicensees, in lieu of the milestone obligations set forth in the ~~first quarter of 2017. This payment was recognized in intangible assets~~agreement. We are obligated under the agreement to use commercially reasonable efforts to develop and ~~will be amortized over the estimated~~commercialize at least one product containing lucitanib, and we are also responsible for all remaining ~~useful life of rucaparib. AstraZeneca will also receive royalties on any net sales of rucaparib.~~development and commercialization costs for lucitanib.

~~On July 31, 2017,~~The license agreement with Advenchen will remain in effect until the expiration of all of our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in a loss of our rights to lucitanib.

FAP-2286 and the Radionuclide Therapy Development Program

In September 2019, we entered into a ~~Master Clinical Trial Collaboration Agreement with Bristol-Myers Squibb Company (“BMS”). This agreement is a clinical~~global license and collaboration agreement with 3BP to ~~evaluate the combination of Bristol-Myers Squibb’s immunotherapy Opdivo~~develop and ~~Clovis’ Rubraca in pivotal phase 3 clinical trials in:~~

Advanced ovarian cancer: First-line maintenance treatment study to evaluate the Rubraca + Opdivo, Rubraca, Opdivo and placebo in newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube or primary peritoneal cancer who have completed platinum-based chemotherapy.

Advanced triple-negative breast cancers (TNBC): First-line study to evaluate Rubraca + Opdivo, Rubraca, Opdivo and chemotherapy in patients with stage IV or recurrent locally advanced inoperable TNBC associated with a homologous recombination deficiency (HRD).

commercialize a PTRT and imaging agent targeting FAP. The collaboration will also include a Phase 2 study to evaluate the safety and efficacy of Opdivo in combination with Rubraca in patients with metastatic castration-resistant prostate cancer (mCRPC). The Opdivo + Rubraca combination with mCRPC will be conductedlead candidate, designated internally as an arm of a larger BMS-sponsored study. The planned multi-arm clinical trials will be conducted in the U.S., Europe and possibly additional countries. Clovis will be the study sponsor and conducting party for the ovarian cancer study and BMS will be the study sponsor and conducting party for the breast and prostate cancer studies.

We are party to other product license agreements for our other drug candidates, lucitanib and rociletinib (see our 2016 Form 10-K for additional details). We and Les Laboratories Servier (“Servier”) are developing lucitanibFAP-2286, is being developed pursuant to a global development plan agreed to ~~between~~by the parties. ~~Servier~~We are responsible for the costs of all preclinical and clinical development activities described in the plan, including the costs for a limited number of 3BP full-time equivalents and external costs incurred during the preclinical development phase of the collaboration. Upon the signing of the license and collaboration agreement in September 2019, we made a $9.4 million upfront payment to 3BP, which we recognized as acquired in-process research and development expense.

Pursuant to the terms of the FAP agreement, we are required to make additional payments to 3BP for annual technology access fees and upon the achievement of certain development and regulatory milestone events (or on certain dates, whichever occur earlier). We are also obligated to pay 3BP single- to low-double-digit royalties on net sales of the FAP-targeted therapeutic product and imaging agent, based on the volume of annual net sales achieved. In addition, 3BP is entitled to receive 34% of any consideration, excluding royalties on the therapeutic product, pursuant to any sublicenses we may grant.

We are obligated under the license and collaboration agreement to use diligent efforts to develop FAP-2286 and commercialize a FAP-targeted therapeutic product and imaging agent, and we are responsible for all commercialization costs in our territory. The agreement with 3BP will remain in effect until the expiration of our royalty obligations to 3BP, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, 3BP can terminate the agreement, resulting in a loss of our rights. 3BP also has the right to terminate the agreement under certain circumstances in connection with our change of control in which the acquiring party retains a

Table of Contents

product competitive with the FAP-targeted therapeutic product or, in the event marketing authorization has not yet been obtained, does not agree to the then-current global development plan.

In February 2020, we finalized the terms of a drug discovery collaboration agreement with 3BP to identify up to 3 additional, undisclosed targets for peptide-targeted radionuclide therapy, to which we will obtain global rights for any resulting product candidates. We are responsible for the costs of all preclinical and clinical development activities conducted under the discovery program, including the costs for ~~lucitanib up to €80.0 million. Cumulative global~~a limited number of 3BP full-time equivalents and external costs incurred during the discovery and preclinical development ~~costs in excess of €80.0 million, if any, will be shared equally between us and Servier. We recorded a $0.1 million and $1.3 million receivable at September 30, 2017 and~~phase for each collaboration target. The discovery collaboration agreement was effective December 31, ~~2016, respectively,~~2019, for ~~the reimbursable development costs incurred under the global development plan,~~ which ~~is included in other current assets on the Consolidated Balance Sheets. For the three months ending September 30, 2017 and 2016,~~ we incurred ~~$0.2~~a $2.1 million technology access fee, which we accrued and ~~$1.3 million, respectively, in~~recognized as a research and development ~~costs~~expense.

Pursuant to the terms of the discovery collaboration agreement, we are required to make additional payments to 3BP for annual technology access fees and ~~recorded reductions~~upon the achievement of certain development and regulatory milestone events (or on certain dates, whichever occur earlier). We are also obligated to pay 3BP a 6% royalty on net sales of License Products (as defined in ~~research~~the agreement), based on the volume of quarterly net sales achieved.

We are obligated under the discovery collaboration agreement to use diligent efforts to develop and commercialize the product candidates, if any, that result from the discovery program, and we are responsible for all clinical development ~~expense~~and commercialization costs. The agreement with 3BP will remain in effect until the expiration of ~~$0.0 million~~our royalty obligations to 3BP, determined on a product-by-product and ~~$1.3 million, respectively, for reimbursable development costs due from Servier. For~~country-by-country basis, unless we elect to terminate the ~~nine months ending September 30, 2017 and 2016,~~agreement earlier. If we incurred $0.6 million and $7.4 million, respectively, in research and development costs and recorded reductions in research and development expense of $1.0 million and $7.7 million, respectively, for reimbursable development costs due from Servier.

~~During~~fail to meet our obligations under the ~~second quarter of 2016, we and Servier agreed to discontinue the development of lucitanib for breast cancer and lung cancer~~agreement and are ~~continuing~~unable to ~~evaluate, what, if any, further development of lucitanib will be pursued. Based on current estimates, we expect to complete~~cure such failure within specified time periods, 3BP can terminate the ~~committed on-going development activities~~agreement, resulting in ~~2017 and expect full reimbursement~~a loss of our ~~development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations.~~rights.

~~Table of Contents~~

~~13.~~14. Net Loss Per Common Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the 2021 Notes, 2025 Notes and 2024 Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):


	Three and Nine months ended September 30,
	2017	2016
Common shares under option	5,696	3,772

			Three and nine months ended September 30,
			2020	2019
Common shares under option plans			3,570	2,460
Convertible senior notes	4,646	4,646	25,648	41,598
Total potential dilutive shares	10,342	8,418	29,218	44,058

~~14.~~

15. Commitments and Contingencies

Royalty and License Fee Commitments

We have entered into certain license agreements, as identified in Note ~~12,~~ 13, License Agreements, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. Our payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, we only recognize payment obligations which are probable and estimable as of the balance sheet date. Milestone liabilities of $21.5 million and $20.1 million are recorded on our Consolidated Balance Sheets at September 30, 2017 and December 31, 2016, respectively, and relate to milestone payments for the licensing of our rucaparib product, which was approved by the FDA on December 19, 2016.

Manufacture and Services Agreement Commitments

On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for Rubraca. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in Rubraca that will be

Table of Contents

updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified in ~~any~~a forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the Rubraca active ingredient. We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of September 30, ~~2017, $177.5~~2020, $68.2 million of purchase commitments exist under the Agreement.

At the time we entered into the Agreement, we evaluated the Agreement as a whole and bifurcated into lease and non-lease components, which consisted of an operating lease of warehouse space, capital lease of equipment, purchase of leasehold improvements and manufacturing costs based upon the relative fair values of each of the deliverables. During October 2018, the production train was placed into service and we recorded the various components of the Agreement.

Legal Proceedings

We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition.

InRociletinib-Related Litigation

Following Clovis’ regulatory announcement in November ~~and December~~ 2015 ~~four purported shareholder class action complaints were filed~~of adverse developments in ~~(or later transferred to) the United States District Court~~its ongoing clinical trials for the District of Colorado. The complaints generally alleged that the Company and certain of its officers violated federal securities laws by making allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib,.

~~Table of Contents~~

~~On February 18, 2016, the Court consolidated the various actions into a single proceeding (“Medina”),~~ ~~under Case No. 1-15-cv-02546,~~ ~~and appointed M. Arkin (1999) LTD and Arkin Communications LTD (the “Arkin Plaintiffs”) as the lead plaintiffs and Bernstein Litowitz Berger & Grossmann LLP as lead counsel for the putative class.~~

On May 6, 2016, the Arkin Plaintiffs filed a consolidated complaint (the “Consolidated Complaint”), adding additional defendants, claims, including under the Securities Act of 1933 (the “Securities Act”) relating to a follow-on offering of Clovis securities in July 2015 (the “July 2015 Offering”), and allegations relating to purportedly false and misleading statements concerning the efficacy and safety profile of rociletinib.

The Company defendants, along with underwriters and venture capital investors also named as defendants in the Consolidated Complaint, filed a motion to dismiss on July 27, 2016. On February 9, 2017, the Medina Court issued an opinion and order granting in part and denying in part the Company defendants’ motion to dismiss, granting in part and denying in part the underwriter defendants’ motion to dismiss, and granting the venture capital investor defendants’ motion to dismiss. On February 22, 2017, the Arkin Plaintiffs filed an amended consolidated class action complaint (the “Amended Complaint”), directed solely at re-pleading its Section 12(a) claims against the underwriter defendants.

On June 18, 2017, the Clovis Defendants entered into a stipulation and agreement of settlement with the Arkin Plaintiffs whereby Clovis will issue to the plaintiffs and participating class members a total consideration comprised of $25.0 million in cash and the issuance of 1,472,324 shares of Clovis common stock (the “Settlement Shares”). The cash portion of the consideration was funded by Clovis’ insurance carriers. At September 30, 2017, the liability for the issuance of the shares and cash, including the amount to be reimbursed through insurance proceeds, was recorded to accrued liability for legal settlement on the Consolidated Balance Sheets in the amount of $142.0 million and a receivable of $25.0 million from the insurance carriers on the Consolidated Balance Sheets. Clovis issued the Settlement Shares on November 2, 2017, whereby the issuance of the shares will be recorded in common stock and additional paid-in capital and the accrued liability for legal settlement will be cleared.

As the settlement agreement is in response to the alleged violation of securities laws by certain of our officers, we have determined that the resulting loss does not relate to activities that are in the normal course of our operations and therefore, should not be recognized in operating losses for the period. Accordingly, we have recognized the entire expense associated to the settlement agreement in legal settlement loss within the other income (expense), net of insurance receivable on the Consolidated Statements of Operations and Comprehensive Loss.

On July 14, 2017, the Medina Court issued an order preliminarily approving the settlement. On September 21, 2017, counsel for the Arkin Plaintiffs and counsel for the Clovis Defendants executed an amendment to the stipulation and agreement of settlement, which provided, among other things, that in the event that lead counsel sells the Settlement Shares, it will be required to liquidate all Settlement Shares, including shares attributable to the settlement class and those attributable to lead counsel’s court-awarded attorneys’ fees.

On October 26, 2017, the Medina Court entered a judgment approving the class action settlement. The judgment certified the putative class for settlement purpose, found that the settlement is fair, reasonable, and adequate in all respects, and subject to certain exclusions and investor opt-outs, releases claims on behalf of the settlement class that were brought or could have been brought in the Medina action and forever bars and enjoins them from prosecuting such claims. Subject to any appeals, the judgment will become final, under the stipulation and agreement of settlement, within 30 days of entry.

On January 22, 2016, the Electrical Workers Local #357 Pension and Health & Welfare Trusts, a purported shareholder of Clovis, filed a purported class action complaint (the “Electrical Workers Complaint”) against Clovis and certain of its ~~officers, directors, investors~~current and ~~underwriters~~former executives were named in various securities lawsuits, the ~~Superior Court~~largest of ~~the State of California, County of San Mateo (the “Electrical Workers Court”). The Electrical Workers Complaint purports to be asserted on behalf of~~which was a putative class ~~of persons who purchased stock in the July 2015 Offering. The complaint~~ ~~asserted claims under certain provisions of the Securities Act relating to the July 2015 Offering based on substantially similar allegations to those asserted in the Medina action. On June 30, 2016, the Electrical Workers Plaintiffs filed an amended complaint adding new allegations (the “Amended Complaint”).~~

~~On July 28, 2016, the defendants filed a motion to stay the Electrical Workers~~ action pending resolution of the Medina action and a demurrer to the Amended Complaint. On September 23, 2016, after hearing oral argument, the Electrical Workers Court granted the motion to stay and reserved on issuing a ruling on defendants’ pending demurrer.

~~Table of Contents~~

The Company believes that the claims asserted in the Electrical Workers Action are released and barred by operation of law through the Medina settlement (discussed above), and accordingly plans to seek dismissal of the Electrical Workers Action on that basis.

On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the offering materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages.

On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.

~~On January 31, 2017, Defendants filed a motion to stay the Antipodean action pending resolution of the Medina action~~lawsuit in the District of ~~Colorado. Defendants also filed a motion to dismiss the Antipodean Amended Complaint~~Colorado (the “Medina Action”) which was settled on ~~March 29, 2017.~~

~~On March 14, 2017, the Clovis Defendants and Antipodean participated in a mediation, which did not result in a settlement.~~

On August 8, 2017, the parties participated in a scheduled hearing on Defendants’ motion to stay and motion to dismiss before Justice Masley of the New York Supreme Court, County of New York. At the hearing, Justice Masley granted Defendants’ motion to stay until after the October 26, 2017 ~~hearing in the Medina action. Per the Court’s August 10, 2017 order, Defendants’ motion to dismiss is held in abeyance and will be deemed submitted on November 1, 2017.~~(the “Medina Settlement”). The remaining actions are discussed below.

~~The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint. However, there can be no assurance that the defense will be successful.~~

~~Clovis received a letter dated May 31, 2016 from an alleged owner of its common stock, which purports to set forth a demand for inspection of certain of our books and records pursuant to~~ ~~8 Del. C.~~ § 220 (the “Macalinao Demand Letter”). Clovis also received a letter dated December 15, 2016 from a second alleged owner of Clovis common stock, which purports to set forth a similar demand for inspectionIn March 2017, 2 putative shareholders of the Company’s books and records pursuant to 8 Del. C. § 220 (the “McKenry Demand Letter”). Both the Macalinao Demand Letter and McKenry Demand Letter were purportedly made for the purposes of investigating alleged misconduct at the Company, ~~relating to rociletinib. The Company produced certain books and records in response to the Macalinao Demand Letter and McKenry Demand Letter in January and February 2017, respectively.~~

~~In March 2017,~~ Macalinao and McKenry (the “Derivative Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation,, Case No, 2017-0222 (the “Consolidated Derivative Action”).

On May 18, 2017, the Derivative Plaintiffs filed a Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint ~~purported to rely on documents produced by the Company in response to the Macalinao Demand Letter and McKenry Demand Letter. The Consolidated Derivative Complaint~~ sought, among other things, an award of money damages.

On July 31, 2017, the defendants filed a motion to dismiss the Consolidated Derivative Complaint. Plaintiffs filed an opposition to the motion to dismiss on August 31, 2017, and the defendants filed a reply in further support of the

~~Table of Contents~~

motion to dismiss on September 26, 2017. ~~No date has been scheduled~~

While the motion to dismiss remained pending, on November 19, 2018, Plaintiffs filed a motion for ~~argument~~leave to file a supplemental consolidated complaint, and on ~~Defendants’~~November 20, 2018, the Court granted that motion. On November 27, 2018, Plaintiffs filed their supplemental complaint (the “Supplemental Derivative Complaint”), which adds allegations concerning the Company’s, Mr. Mahaffy’s and Mr. Mast’s settlements with the United States Securities and Exchange Commission. Pursuant to a briefing schedule entered by the Court, the defendants filed a supplemental motion to dismiss the ~~Consolidated~~Supplemental Derivative ~~Complaint.~~Complaint on February 6, 2019; plaintiffs filed an opposition brief on February 22, 2019; and the defendants filed a reply brief on March 5, 2019. The Court held oral arguments on the defendants’ motions to dismiss on June 19, 2019. At the oral arguments, the Court ordered the parties to submit supplemental letter briefs on the motion to dismiss.

Table of Contents

Derivative Complaint was dismissed as to ~~vigorously defend against~~Plaintiffs’ derivative claims for unjust enrichment and insider trading. The Court allowed Plaintiffs’ remaining derivative claim for breach of fiduciary duty to proceed. Defendants filed an answer to the ~~allegations~~Supplemental Derivative Complaint on December 27, 2019.

On December 17, 2019, the parties participated in a mediation, which did not result in a settlement. On December 22, 2019, the Company’s board of directors formed a Special Litigation Committee (the “SLC”) to conduct an investigation of the claims asserted in the Supplemental Derivative Complaint. On February 18, 2020, the SLC moved to stay all proceedings in the Consolidated Derivative ~~Complaint, but there can be no assurance~~Action pending completion of its investigation. Plaintiffs filed their opposition to the motion to stay on March 3, 2020 and the SLC filed its reply on March 13, 2020. On May 12, 2020, after hearing oral argument, Vice Chancellor Slights granted the SLC’s motion to stay proceedings until September 18, 2020 so that the ~~defense will be successful.~~SLC may complete its investigation. On September 11, 2020, Vice Chancellor Slights granted the parties’ request to extend the stay until October 31, 2020, to allow the SLC further time to complete its investigation. On October 26, 2020, Vice Chancellor Slights granted the parties’ request to further extend the stay until November 15, 2020.

~~On May 10, 2017, John Solak, a purported shareholder of~~While the SLC’s investigation remains ongoing, the Company ~~filed~~does not believe this litigation will have a ~~shareholder derivative complaint in the Court~~material impact on its financial position or results of Chancery of the State of Delaware (the “Solak Complaint”) against certain directors and an officer of the Company. The Solak Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by adopting a compensation plan that overcompensated the non-employee director defendants, in relation to companies of comparable market capitalization and size. The Solak Complaint also alleged claims of waste of corporate assets and unjust enrichment due to this allegedly wrongful compensation plan. The Solak Complaint sought, among other things, an award of money damages and the imposition of corporate governance reforms.operations.

On September 27, 2017, the Court entered an order extending the defendants’ time to respond to the Solak Complaint to October 31, 2017 based on, among other factors, the fact that the parties are engaged in discussions in an effort to resolve the Solak action. On October 31, 2017, the parties submitted a joint stipulation and proposed order to the Court seeking a further extension of the defendants’ response deadline to November 30, 2017, which order was entered by the Court on November 1, 2017.

The Company intends to vigorously defend against the allegations in the Solak Complaint, if the parties are unable to reach a consensual resolution, but there can be no assurance that the defense will be successful.

On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages.

On ~~June 19, 2017,~~September 29, 2020, Judge R. Brooke Jackson dismissed plaintiff’s Section 14(a) claim with prejudice. Judge Jackson also dismissed plaintiff’s breach of fiduciary duty claim with leave to re-file in the ~~parties filed a joint motion to stay the Guo action pending resolution~~Delaware Court of ~~the motion to dismiss~~Chancery, where the Consolidated Derivative ~~Complaint. On~~Action, which alleges virtually identical claims, remains pending.

European Patent Opposition

Oppositions were filed in the granted European counterparts of 2 patents in the rucaparib camsylate salt/polymorph patent family. An opposition of European patent 2534153 was filed by 2 opponents on June 20, ~~2017,~~2017. The European Patent Office’s Opposition Division held an oral hearing on December 4, 2018, during which it upheld claims, narrowed from the ~~court~~originally granted patent, to certain crystalline forms of rucaparib camsylate, including, but not limited to, rucaparib S-camsylate Form A, the ~~motion~~crystalline form in Rubraca. Clovis and 1 opponent, Hexal, appealed the written decision of the European Opposition Division and filed reply appeal briefs in early November 2019. An opposition of European patent 3150610, a divisional patent of European patent 2534153, was filed on April 30, 2020. The divisional patent includes claims directed to ~~stay.~~

use of rucaparib camsylate or rucaparib maleate in a method of inhibiting PARP activity or treating cancer. The ~~Company intends~~grounds of opposition for the divisional patent were lack of novelty, lack of inventive step, added subject matter, and insufficient disclosure – similar grounds on which the parent patent was opposed. It is common for an opponent to ~~vigorously defend against~~raise these grounds in an opposition. During examination, the ~~allegations~~European Patent Office considers all of these grounds and considered the application to comply with the applicable law when granting the patent. In particular, the novelty and inventive step challenges to the divisional patent are based on prior art references (or closely related disclosures) that were cited by the European patent examiner during prosecution of the application. As part of the proceeding, we have the opportunity to submit further arguments and pursue alternative claims in the ~~Guo Complaint, but there~~form of auxiliary requests. While the ultimate results of patent challenges can be ~~no assurance that the defense will~~difficult to predict, we believe a number of factors support patentability and we believe a successful challenge of all claims would be ~~successful.~~

~~In addition, the Company has received inquiries and requests~~difficult. The date for information from governmental agencies, including the U.S. Securities and Exchange Commission and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. The Company is continuing to cooperate with these agencies with respect to their investigations. The proposed settlement of the Medina action does not resolve these inquiries and the Company cannot predict their timing or outcome.

~~15. Subsequent Events~~

On October 26, 2017, the stipulation and agreement of settlement between the Clovis Defendants and the Arkin Plaintiffs was approved. Under the terms of the settlement, participating class members will receive total consideration comprised of $25.0 million in cash and the issuance of 1,472,324 Settlement Shares. The cash portion of the consideration was funded by Clovis’ insurance carriers. At September 30, 2017, the liability for the issuance of the shares and cash, including the amount to be reimbursed through insurance proceeds, was recorded to accrued liability for legal settlement on the Consolidated Balance Sheetsresponse in the ~~amount of $142.0 million~~divisional patent is December 28, 2020. In Europe, regulatory exclusivity is available for ten years, plus one year for a new indication, therefore, we have regulatory exclusivity for Rubraca in Europe until 2028, and a receivable of $25.0 million from the insurance carriers on the Consolidated Balance Sheets. On November 2, 2017, we issued 1,472,324 shares of Clovis common stock and recorded the issuance of shares in common stock andif an additional ~~paid-in capital. In addition,~~indication is approved, until 2029.

2029

Table of Contents

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

~~we cleared the $142.0 million accrued liability and the $25.0 million receivable from the insurance carriers in October 2017.~~

~~ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS~~

Forward-Looking Information

This Quarterly Report on Form 10-Q and the information incorporated herein by reference includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the market acceptance and commercial viability of our approved product, the development and performance of our sales and marketing capabilities, the performance of our clinical trial partners, third party manufacturers and our diagnostic partners, our ongoing and planned non-clinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, including our ability to confirm clinical benefit and safety of our approved product through confirmatory trials and other post-marketing requirements, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, expectations regarding sales of our products, our results of operations, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate, including our competition and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein.

Any forward-looking statements that we make in this Quarterly Report on Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

You should also read carefully the factors described in the “Risk Factors” in Part I, Item 1A in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”), as supplemented by the risk factors set forth herein, as updated from time to time in our subsequent SEC filings, to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. You are advised, however, to consult any further disclosures we make on related subjects in our Quarterly Reports on From 10-Q, Current Reports on Form 8-K and our website.

~~Overview~~Clovis Oncology®, the Clovis logo and Rubraca® are trademarks of Clovis Oncology, Inc. in the United States and in other selected countries. All other brand names or trademarks appearing in this report are the property of their respective holders. Unless the context requires otherwise, references in this report to “Clovis,” the “Company,” “we,” “us” and “our” refer to Clovis Oncology, Inc., together with its consolidated subsidiaries.

Overview

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

Our ~~commercial~~marketed product ~~Rubraca® (rucaparib) is the first and only~~Rubraca, an oral small molecule inhibitor of poly ADP-ribose polymerase ~~or PARP, inhibitor of PARP1, PARP2 and PARP3 approved~~(“PARP”), is marketed in the United States byfor two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and also an indication specific to metastatic castration-resistant prostate cancer (“mCRPC”). The initial indication received approval from the FDA ~~as monotherapy for~~in December 2016 and covers the treatment of adult patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) ~~associated advanced~~-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies

Table of Contents

and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. In April 2018, the FDA also approved Rubraca for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The approval in this second, broader and earlier-line indication on a priority review timeline was based on positive data from the phase 3 ARIEL3 clinical trial. Diagnostic testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

~~Rucaparib~~In May 2018, the European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum-based chemotherapy. In January 2019, the European Commission granted a variation to the marketing authorization to include the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. With this approval, Rubraca is ~~being studied~~now authorized in the EU for certain patients in the recurrent ovarian cancer maintenance setting regardless of their BRCA mutation status. Following successful reimbursement negotiations, we have launched Rubraca in each of Germany, United Kingdom, Italy, France and Spain.

In May 2020, the FDA approved Rubraca tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated mCRPC who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The FDA approved this indication under accelerated approval based on objective response rate and duration of response data from the multi-center, single arm TRITON2 clinical trial. We have launched Rubraca for prostate cancer in the U.S. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. The TRITON3 clinical trial is expected to serve as the confirmatory study for the Rubraca accelerated approval in mCRPC. In August 2020, the FDA approved the use of Foundation Medicine’s plasma diagnostic detection of deleterious BRCA mutation (germline and/or somatic) to select mCRPC patients for treatment with Rubraca.

In October 2020, we adopted a ~~potential maintenance therapy~~new U.S. commercial strategy to address a challenging sales environment resulting from a trend toward reduced in-person access for oncology commercial teams to oncology practices in general, which has been further accelerated by COVID-19, which has severely limited oncology patient visits and cancer diagnoses. Physicians increasingly prefer digital communications and virtual peer-to-peer interactions which they can access when they choose. The new hybrid strategy elevates digital programming, virtual communication and peer-to-peer interactions while reducing in-person promotion, and the remaining in-person activities will be much more targeted. This hybrid strategy does not require as large a U.S. commercial organization, and in early November the size of the organization was reduced by approximately 45 employees, resulting in a U.S. team of approximately 85 employees.

We anticipate clinical data from our ARIEL4 confirmatory ovarian cancer study in December 2020. ARIEL4 is a Phase 3 multicenter, randomized study of Rubraca versus chemotherapy, which is enrolling relapsed ovarian cancer patients ~~in the ARIEL3 trial. On June 19, 2017, we announced that the ARIEL3 trial successfully achieved the~~with BRCA mutations (inclusive of germline and/or somatic) who have failed two prior lines of therapy. The primary endpoint of ~~improved PFS by investigator review in each of three populations studied. PFS was also improved in~~ the ~~rucaparib group compared with placebo by BICR,~~study is progression-free survival. This study represents a key secondary endpoint. Based on these findings, we submitted a sNDA in October 2017 for a second-line or later maintenance treatment indication for all women with platinum-sensitive ovarian cancer who have respondedpost marketing commitment to their most recent platinum therapy. Rucaparib is also being developed in patients with mutant BRCA tumors and other DNA repair deficiencies beyond BRCA – commonly referred to as homologous recombination

~~Table of Contents~~

~~deficiencies. Studies open for enrollment or under consideration include prostate, breast, pancreatic, gastroesophageal, bladder and lung cancers.~~

~~Our MAA for rucaparib that we submitted to~~support the ~~EMA for an ovarian cancer treatment indication is currently under review.~~ ~~We anticipate an opinion from the CHMP in late 2017, and, if we receive a favorable opinion from the CHMP, a potential~~conditional approval ~~from the EMA may follow during the first quarter of 2018. Following a potential approval~~granted for the treatment indication in the EU, including ensuring that sufficient partially platinum-sensitive patients are enrolled in the trial.

Beyond our labeled indications, we ~~intend~~have a clinical development program underway to ~~submit~~further evaluate Rubraca in a ~~variation~~variety of solid tumor types, either as monotherapy or in combination with other agents, including several studies as part of our ongoing clinical collaboration with Bristol Myers Squibb to evaluate its immunotherapy OPDIVO® (nivolumab) in combination with Rubraca. We anticipate initial data of Rubraca monotherapy versus placebo from our ATHENA study in the ~~MAA~~second half of 2021, with the results of Rubraca versus OPDIVO in all study populations a year or more later.

We initiated the Phase 2 LODESTAR study in December 2019 to evaluate Rubraca in homologous recombination repair genes across tumor types. The study is evaluating rucaparib as monotherapy treatment in patients with recurrent solid tumors associated with a deleterious mutation in homologous recombination repair genes. Based on our interactions with the FDA, we believe that this study may be registration-enabling for a targeted gene- and tumor-agnostic label, if data from the ~~second-line or later maintenance treatment~~trial support the potential for an accelerated approval. Assuming enrollment in this study continues as planned, we may potentially file a supplemental New Drug Application with the FDA for this indication in the second half of 2021.

Table of Contents

The newest Phase 3 clinical trial for Rubraca is the CASPAR study, sponsored by the Alliance for Clinical Trials in Oncology which ~~we anticipate~~is part of the National Cancer Institute. CASPAR is a ~~potential approval during~~Phase 3 study comparing Enzalutamide and Rubraca to Enzalutamide and placebo as a novel therapy in first line mCRPC in an all-comers population of approximately 1000 patients. CASPAR is expected to begin enrolling patients in the ~~third quarter of 2018.~~

near-term. We hold worldwide rights ~~for rucaparib. In June 2011, we obtained an exclusive, worldwide license from Pfizer~~ to develop and commercialize rucaparib. U.S. Patent 6,495,541, and its equivalent counterparts issued in dozens of countries, directed to the rucaparib composition of matter, expire in 2020 and are potentially eligible for up to five years patent term extension in various jurisdictions. We believe that patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Act, could be available to extend our patent exclusivity for rucaparib to the fourth quarter of 2023 in the United States. In Europe, we believe that patent term extension under a supplementary protection certificate could be available for an additional five years to at least 2025. In April 2012, we obtained an exclusive license from AstraZeneca under a family of patents and patent applications to permit the development and commercialization of rucaparib for certain methods of treating patients with PARP inhibitors. Additionally, other patents and patent applications are directed to methods of making, methods of using, dosing regimens, various salt and polymorphic forms and formulations and have expiration dates ranging from 2020 through potentially 2035, including the camsylate salt/polymorph patent family licensed from Pfizer, which expires in 2031 and a patent application directed to high dosage strength rucaparib tablets that, if issued, will expire in 2035. We are aware of a number of cases where salt and polymorph patents have been challenged. Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. European oppositions are commonly filed against patents related to pharmaceutical products. The grounds of opposition related to Rubraca were lack of novelty and lack of inventive step. The novelty and inventive step challenges are based on prior art references (or closely related disclosures) that were previously raised by the European patent examiner during prosecution of the application. The claims of the granted patent were found to be patentable over this prior art. While the ultimate results of patent challenges can be difficult to predict, we believe a number of factors, including a constellation of unexpected properties, support the novelty and non-obviousness of our rucaparib camsylate salt/polymorph composition of matter patent. Based on these factors, we believe a successful challenge of that patent would be difficult.Rubraca.

In addition to Rubraca, we have ~~two other~~a second product ~~candidates: lucitanib,~~candidate currently in clinical development. Lucitanib is an investigational, oral, potent angiogenesis inhibitor ~~of the tyrosine kinase activity of~~which inhibits vascular endothelial growth factor receptors ~~(VEGFR) 1-3,~~1 through 3 (“VEGFR1-3”), platelet-derived growth factor receptors ~~(PDGFR)~~ alpha and beta (“PDGFR α/β”) and fibroblast growth factor receptors ~~(FGFR) 1-3,~~1 through 3 (“FGFR1-3”). We believe that data for a drug similar to lucitanib that inhibits these same pathways – when combined with a PD-1 inhibitor – represent a scientific rationale for development of lucitanib in combination with a PD-1 inhibitor, and ~~rociletinib, an oral mutant-selective inhibitor~~in February 2019, lucitanib was added to our clinical collaboration with Bristol Myers Squibb. Encouraging data of ~~epidermal growth factor receptor (EGFR). While~~VEGF and PARP inhibitors in combination also supports the evaluation of lucitanib combined with Rubraca. Thus, we have ~~stopped enrollment~~two Phase 1b/2 combination studies involving lucitanib underway, which consist of the following: the Clovis-sponsored LIO-1 study of lucitanib in ~~ongoing trials for each~~combination with nivolumab in advanced solid tumors and gynecologic cancers, which is currently enrolling patients in the Phase 2 part of ~~these candidates, we continue~~the study; and an arm of the Clovis-sponsored SEASTAR study evaluating lucitanib in combination with Rubraca in advanced solid tumors and ovarian cancer. We expect to ~~provide drugs to patients whose clinicians recommend continuing therapy.~~present interim data from the Clovis-sponsored LIO-1 study of lucitanib in combination with nivolumab at medical meetings in 2021. We ~~maintain certain~~hold the global (excluding China) development and commercialization rights for lucitanib.

In September 2019, we entered into a license and collaboration agreement with 3BP to develop a peptide-targeted radionuclide therapy (“PTRT”) and imaging agent targeting fibroblast-activating protein alpha (“FAP”). FAP is highly expressed by cancer-associated fibroblasts found in a majority of tumor types, potentially making it a suitable target across a wide array of solid tumors. PTRT is an emerging class of drugs and it involves the injection of a small amount of radioactive material – a radionuclide – that is combined with a cancer-targeting peptide for use as a targeted radiopharmaceutical. The targeting peptide is able to recognize and bind to specific receptors on the cancer cell, such as antigens and cell receptors. When used in a targeted radiopharmaceutical, the peptide is designed to attach to cancer cells, and the intended result is to deliver a high dose of radiation to the tumor while sparing normal tissue because of its rapid systemic clearance. In order for the targeted radiopharmaceutical to be safe and efficacious, it must rapidly attach to cancer cells or in close vicinity to the cancer cells, be retained in or at the tumor site for a sufficient period of time that the radionuclide can have activity on the cancer cells, have minimal attachment to non-cancer cells and then be rapidly cleared from the body.

Following completion of preclinical work to support an investigational new drug application (“IND”) for the lead candidate under our license and collaboration agreement, designated internally as FAP-2286, we plan to conduct a broad clinical development program. We anticipate submitting two INDs for FAP-2286 for use as imaging and treatment agents, respectively, in Q4 2020 to support an initial Phase 1 study to determine the dose and tolerability of FAP-2286 as a therapeutic agent with expansion cohorts planned in multiple tumor types as part of a global development program. The FAP-targeting imaging agent will be utilized to identify tumors that contain FAP for treatment in the Phase 1 clinical study, which we anticipate initiating in 2021. In addition to our planned studies, an academic institution in the U.S. is sponsoring a separate imaging-only study with FAP-2286 to evaluate FAP expression in multiple tumor types; their IND has been authorized and they expect to initiate their study in the near term. We hold U.S. and global rights to FAP-2286, excluding Europe (defined to include Russia, Turkey and Israel), where 3BP retains rights. We also have agreed with 3BP to collaborate on a discovery program directed to up to three additional, undisclosed targets for peptide-targeted radionuclide therapy, to which we would obtain global rights for any resulting product candidates.

In September 2020, data for our three compounds were presented as e-posters at the European Society for Medical Oncology (“ESMO”) Virtual Congress 2020. These include initial data from the Phase 1b part of the LIO-1 study of lucitanib in combination with OPDIVO, new analyses of data from the pivotal Rubraca ARIEL3 and TRITON2 studies, initial data from the Phase 1b part of the SEASTAR study arm of Rubraca with Trodelvy™ (sacituzumab govitecan-hziy) and the first presentation of preclinical data for FAP-2286 Clovis’ novel peptide-targeted radionuclide therapy.

Data presented from the Phase 1b part of the Phase 1b/2 LIO-1 study in patients with an advanced solid tumor (n=17) identified the recommended starting Phase 2 dose of oral lucitanib to be used in combination with OPDIVO and showed promising signs of antitumor activity. Across three dose levels studied (6 mg, 8 mg and 10 mg) of oral lucitanib in combination with intravenous (IV) OPDIVO at (480 mg once every 28 days), only one dose-limiting toxicity of Grade

Table of Contents

3 proteinuria was observed among 17 patients, and there were no apparent differences in treatment-emergent adverse event (“TEAE”) frequencies between dose levels. In this small patient population, TEAEs were consistent with those expected for lucitanib and ~~global development~~OPDIVO. Grade 3 TEAEs included hypertension (n=4), diarrhea (n=1), and ~~commercialization rights~~proteinuria (n=1); treatment-emergent hypertension was otherwise grade 1 or 2 (n=4), and readily managed with close monitoring and early hypertensive therapy. No grade ≥4 adverse events were reported. Given lucitanib’s relatively large inter-patient pharmacokinetic variability, a safety-based dose-titration approach is being used for ~~rociletinib.~~the Phase 2 part of the study to optimize lucitanib efficacy as well as safety and tolerability. Among the 17 patients treated, 15 were evaluable for RECIST response as of the efficacy cut-off date: these include one patient with a confirmed complete response, one patient with a confirmed partial response, 10 patients have had a best response of stable disease and three patients had progressive disease.

In addition to data from the Phase 1b part of the LIO-1 study, a Trials in Progress (“TiP”) poster describing the study design of the Phase 2 part of LIO-1 was presented. The Phase 2 part of the study is currently enrolling patients to evaluate the efficacy and safety of the lucitanib and OPDIVO combination in patients with advanced gynecological solid tumors, including ovarian, endometrial and cervical cancers. A safety-based dose-titration approach is being used for lucitanib dosing to manage tolerability and maintain dose intensity.

New safety data analyses from the pivotal Rubraca studies ARIEL3 and pharmacokinetic (“PK”) analyses of TRITON2 provided additional information to healthcare professionals that can help support their ovarian and prostate cancer patients being treated with Rubraca.

The ARIEL3 data presented in an e-poster reinforce the overall safety profile of Rubraca as a maintenance treatment in patients with recurrent ovarian cancer. After two years of additional follow up for those patients who continued on treatment in the study, the safety profile remained consistent with previous reports, with no new safety signals identified. As of the safety data cutoff, 33 of 372 and 1 of 189 patients in the safety population were still receiving Rubraca or placebo, respectively. Median treatment duration was 8.3 months in the Rubraca arm and 5.5 months in the placebo arm. Prevalence of any-grade nausea declined progressively over the 24-month evaluation period, and prevalence of any-grade anemia/decreased hemoglobin peaked at month 4, decreasing to a plateau after month 8. The first onset of frequently reported TEAEs generally occurred early in treatment (≤45 days). The median duration of the first event of frequently reported TEAEs was generally <60 days.

Population PK analyses of 199 men with mCRPC receiving Rubraca in the TRITON2 study suggest there is no difference in Rubraca PK in men with mCRPC and women with ovarian cancer based on a comparison to a previously-developed model that used data from 454 women with ovarian cancer treated with Rubraca. Also, a higher maximum concentration of Rubraca in the blood was not associated with increased rates of most safety endpoints analyzed, including hematologic adverse events. These PK data and exposure and safety/efficacy correlations using data from the TRITON2 study support the use of Rubraca in eligible mCRPC patients with a starting dose of 600 mg twice daily. TRITON2 served as the pivotal data supporting the May 2020 FDA approval of Rubraca as the first PARP inhibitor for patients with advanced mCRPC associated with a BRCA mutation.

Investigators also presented initial data from the arm of the Phase 1b/2 SEASTAR study evaluating Rubraca in combination with Trodelvy in patients with advanced solid tumors (n=6). Data from the Phase 1b part of the study suggest encouraging initial antitumor activity for the novel combination, including patients with prior PARP inhibitor exposure and without a deleterious homologous recombination repair gene mutation. Despite early toxicities, including dose-limiting neutropenia in two of the three patients in the higher dose cohort, all six patients continued treatment for at least 12 weeks, with side effects effectively managed with dose modification and/or growth factor support. One patient remained on treatment as of the August 11, 2020 data cut-off date. All patients had a best response of stable disease or better, including three patients with a confirmed partial response (all three had been previously treated with a PARP inhibitor).

And finally, the first data from a preclinical evaluation of FAP-2286, Clovis’ novel peptide-targeted radionuclide therapy to FAP were presented. The data showed that FAP-2286 potently and selectively binds FAP. Compelling anti-tumor activity was observed with 177Lu-FAP-2286 (Lutetium-177 conjugated to FAP-2286 for therapeutic use) in FAP-expressing tumor models.

We commenced operations in April 2009. To date, we have devoted substantially all of our resources to identifying and in-licensing product candidates, performing development activities with respect to those product

Table of Contents

candidates and the general and administrative support of these operations. ~~Through~~For the nine months ended September 30, ~~2017,~~2020 and 2019, we have generated ~~$13.6~~$121.2 million ~~in license~~ and ~~milestone revenue related to our collaboration and license agreement with Servier and have generated $38.5~~$103.7 million, ~~net~~respectively, in product revenue related to sales of ~~Rubraca, which~~Rubraca.

We have never been profitable and, as of September 30, 2020, we ~~began to commercialize on December 19, 2016.~~ had an accumulated deficit of $2,513.8 million. We incurred net losses of $270.3 million and $300.9 million for the nine months ended September 30, 2020 and 2019, respectively. We had cash and cash equivalents totaling $224.7 million at September 30, 2020.

We have principally funded our operations using the net proceeds from ~~the sale of convertible preferred stock, the issuance of convertible promissory notes,~~ public offerings of our common stock, ~~and our~~ convertible senior notes ~~offering.~~

~~We have never been profitable~~offerings and as of September 30, 2017, we had an accumulated deficit of $1,425.6 million. We incurred net losses of $294.5 million and $278.4 million for the nine months ended September 30, 2017 and 2016, respectively. The net loss for the nine months ended September 30, 2017 included a charge of $117.0 millionour financing agreement related to a legal settlement. The net loss for the nine months ended September 30, 2016 included a charge of $104.5 million for the impairment of intangible asset and a gain of $24.9 million from a reduction in fair value of contingent purchase consideration. We had cash, cash equivalents and available-for-sale securities totaling $628.0 million at September 30, 2017.

~~Table of Contents~~

our ATHENA trial. We expect to incur significant losses for the foreseeable future, as we incur costs related to commercial activities associated with Rubraca. In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and, if approved by the EMA, in Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on ~~our~~ current estimates, we believe that our cash, cash equivalents, ~~and~~ available-for-sale securities and liquidity available under our financing agreement related to our ATHENA trial will allow us to fund ~~activities~~our operating plan through at least the next 12 months. Until we can generate a sufficient amount of revenue from Rubraca, we expect to finance our operations in part through additional public or private equity or debt offerings and may seek additional capital through arrangements with strategic partners or from other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.

~~Product~~ License Agreements

Rucaparib

In June 2011, we entered into a ~~worldwide~~ license agreement with Pfizer ~~Inc.~~ to obtain the exclusive global rights to develop and commercialize ~~rucaparib, a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), used for the treatment of selected solid tumors.~~Rubraca. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of ~~rucaparib, discussed below,~~Rubraca, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense.

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st1st Indication in US and (ii) EMA approval of an MAA for 1st1st Indication in the EU, to a date that is 18 months after the date of achievement of such milestones. ~~In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones.~~

On December 19, 2016, ~~the~~Rubraca received its initial FDA approved Rubraca (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. The FDAapproval. This approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was ~~made~~paid in the first quarter of 2017. ~~The~~This FDA approval also resulted in ~~the~~an obligation to pay a $20.0 million milestone payment, for which we ~~have~~ exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. We paid the $23.0 million milestone payment in June 2018.

In April 2018, Rubraca received a second FDA approval. This approval resulted in an obligation to pay a $15.0 million milestone payment, which we paid in April 2018.

In May 2018, Rubraca received its initial European Commission marketing authorization. This approval resulted in an obligation to pay a $20.0 million milestone payment, which we paid in June 2018.

In January 2019, Rubraca received a second European Commission approval. This approval resulted in an obligation to pay a $15.0 million milestone payment, which we paid in February 2019.

In June 2019, we paid a $0.75 million milestone payment due to the launch of Rubraca as maintenance therapy in Germany in March 2019.

These milestone payments were recognized as intangible assets and ~~will be~~are amortized over the estimated remaining useful life of Rubraca.

Table of Contents

Lucitanib

We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of ~~rucaparib~~lucitanib, based on ~~December 19, 2016 resulted in a $0.35 million~~

~~Table~~the volume of ~~Contents~~

~~milestone obligation~~annual net sales achieved. In addition, after giving effect to ~~AstraZeneca as required by~~the first and second amendments to the license agreement, ~~which was paid~~we are required to pay to Advenchen 25% of any consideration, excluding royalties, we receive from sublicensees, in lieu of the milestone obligations set forth in the ~~first quarter~~agreement. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib.

The license agreement with Advenchen will remain in effect until the expiration of ~~2017. This payment was recognized~~all of our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in ~~intangible assets~~a loss of our rights to lucitanib.

FAP-2286 and ~~will be amortized over~~ the ~~estimated remaining useful life of rucaparib. AstraZeneca will also receive royalties on any net sales of rucaparib.~~Radionuclide Therapy Development Program

~~On July 31, 2017,~~In September 2019, we entered into a ~~Master Clinical Trial Collaboration Agreement~~global license and collaboration agreement with ~~Bristol-Myers Squibb Company (“BMS”)~~3BP to develop and commercialize a PTRT and imaging agent targeting FAP. The lead candidate, designated internally as FAP-2286, is being developed pursuant to a global development plan agreed to by the parties. We are responsible for the costs of all preclinical and clinical development activities described in the plan, including the costs for a limited number of 3BP full-time equivalents and external costs incurred during the preclinical development phase of the collaboration. Upon the signing of the license and collaboration agreement in September 2019, we made a $9.4 million upfront payment to 3BP, which we recognized as acquired in-process research and development expense.

Table of Contents

Pursuant to the terms of the FAP agreement, we are required to make additional payments to 3BP for annual technology access fees and upon the achievement of certain development and regulatory milestone events (or on certain dates, whichever occur earlier). ~~This agreement~~We are also obligated to pay 3BP single- to low-double-digit royalties on net sales of the FAP-targeted therapeutic product and imaging agent, based on the volume of annual net sales achieved. In addition, 3BP is ~~a clinical~~entitled to receive 34% of any consideration, excluding royalties on the therapeutic product, pursuant to any sublicenses we may grant.

We are obligated under the license and collaboration agreement to ~~evaluate~~use diligent efforts to develop FAP-2286 and commercialize a FAP-targeted therapeutic product and imaging agent, and we are responsible for all commercialization costs in our territory. The agreement with 3BP will remain in effect until the ~~combination~~expiration of ~~Bristol-Myers Squibb’s immunotherapy Opdivo~~our royalty obligations to 3BP, determined on a product-by-product and ~~Clovis’ Rubraca~~country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, 3BP can terminate the agreement, resulting in ~~pivotal phase 3 clinical trials in:~~a loss of our rights. 3BP also has the right to terminate the agreement under certain circumstances in connection with our change of control in which the acquiring party retains a product competitive with the FAP-targeted therapeutic product or, in the event marketing authorization has not yet been obtained, does not agree to the then-current global development plan.

~~The collaboration will also include a Phase 2 study to evaluate~~In February 2020, we finalized the safety and efficacy of Opdivo in combination with Rubraca in patients with metastatic castration-resistant prostate cancer (mCRPC). The Opdivo + Rubraca combination with mCRPC will be conducted as an armterms of a ~~larger BMS-sponsored study.~~drug discovery collaboration agreement with 3BP to identify up to three additional, undisclosed targets for peptide-targeted radionuclide therapy, to which we will obtain global rights for any resulting product candidates. We are responsible for the costs of all preclinical and clinical development activities conducted under the discovery program, including the costs for a limited number of 3BP full-time equivalents and external costs incurred during the discovery and preclinical development phase for each collaboration target. The ~~planned multi-arm clinical trials will be conducted~~discovery collaboration agreement was effective December 31, 2019, for which we incurred a $2.1 million technology access fee, which we accrued and recognized as a research and development expense.

Pursuant to the terms of the discovery collaboration agreement, we are required to make additional payments to 3BP for annual technology access fees and upon the achievement of certain development and regulatory milestone events (or on certain dates, whichever occur earlier). We are also obligated to pay 3BP a 6% royalty on net sales of License Products (as defined in the ~~U.S.~~agreement), ~~Europe and possibly additional countries. Clovis will be~~based on the ~~study sponsor and conducting party for the ovarian cancer study and BMS will be the study sponsor and conducting party for the breast and prostate cancer studies.~~volume of quarterly net sales achieved.

We are ~~party~~obligated under the discovery collaboration agreement to ~~other~~use diligent efforts to develop and commercialize the product candidates, if any, that result from the discovery program, and we are responsible for all clinical development and commercialization costs. The agreement with 3BP will remain in effect until the expiration of our royalty obligations to 3BP, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, 3BP can terminate the agreement, resulting in a loss of our rights.

Pursuant to terms of each of our product license agreements, ~~for~~we will pay royalties to our ~~other drug candidates, lucitanib and rociletinib (see our 2016 Form 10-K for additional details).~~licensors on sales, if any, of the respective products.

Financial Operations Overview

Revenue

Product revenue is derived from sales of our product, Rubraca, in the United ~~States.~~ States and Europe. We distribute our product ~~in the U.S.~~ principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently ~~resell~~sell our products to patients and healthcare providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and other discounts. Revenue is recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns (collectively, ~~“sales deductions”~~“variable considerations”). ~~We only recognize revenue on~~Revenue from product sales ~~once the~~are recognized when customers obtain control of our product, ~~is resold~~which occurs at a point in time, typically upon delivery to the ~~patient or healthcare provider by~~customers. For further discussion of our revenue recognition policy, see Note 2, Summary of Significant Accounting Polices in the ~~specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns.~~Revenue Recognition section.

~~Sales Deductions~~

Estimating sales deductions requires significant judgments about future events and uncertainties, and requires us to rely heavily on assumptions, as well as historical experience. Estimated sales deductions are provided for the following:

~~Rebates.~~ Rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare coverage gap program. Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. The accrual for rebates is based on statutory discount rates and known sales to specialty pharmacy patients, or expected utilization for specialty distributor sales to healthcare providers. As we gain more historical experience, the accrual will be based solely on the expected utilization from historical data we have accumulated since the Rubraca product launch. Rebates are generally invoiced and paid quarterly in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known or estimated prior quarters’ unpaid rebates. If actual future rebates vary from estimates, we may need to adjust balances of such rebates to reflect our actual expenditures with respect to these programs, which would affect revenue in the period of adjustment.

~~Table of Contents~~

~~Chargebacks.~~ Chargebacks are discounts that occur when contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service organizations and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the healthcare provider. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates and known sales to specialty distributors adjusted for the estimated utilization by healthcare providers.

~~Discounts.~~ Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts from product sales when revenue is recognized. Service fees are recorded as a selling expense when product sales occur.

~~Co-pay assistance.~~ Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. The intent of this program is to reduce the patient’s out of pocket costs. Liabilities for co-pay assistance are based on actual program participation and estimates of program redemption using data provided by third-party administrators.

~~Returns.~~ Sales of our products are not subject to a general right of return at the point we recognize revenue, which is the point the product is sold to the patient or healthcare provider. To date, we have had minimal product returns and we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience.

In the three and nine months ended September 30, ~~2017,~~2020, we recorded ~~net~~ product revenue of ~~$16.8~~$38.8 million and ~~$38.5~~$121.2 million, respectively, related to sales of ~~Rubraca, which we began to commercialize on December 19, 2016.~~Rubraca. Our ability to generate revenue and become profitable depends upon our ability to successfully commercialize products. Any inability on our part to successfully commercialize Rubraca in the United States, Europe and any foreign territories where it may be approved, or any significant delay in such

Table of Contents

approvals, could have a material adverse impact on our ability to execute upon our business strategy and, ultimately, to generate sufficient revenues from Rubraca to reach or maintain profitability or sustain our anticipated levels of operations.

~~Cost~~We supply commercially labeled Rubraca free of ~~Sales – Product~~

~~We recorded~~charge to eligible patients who qualify due to financial need through our patient assistance program and the majority of these patients are on Medicare. This product ~~cost of sales from sales of Rubraca~~is distributed through a separate vendor who administers the program on our behalf. It is not distributed through our specialty distributor and specialty pharmacy network. This product is neither included in the ~~three~~transaction price nor the variable considerations to arrive at product revenue. Manufacturing costs associated with this free product is included in selling, general and administrative expenses. For the nine months ended September 30, ~~2017.~~ 2020, the supply of this free drug was approximately 17% of the overall commercial supply or the equivalent of $21.8 million in commercial value.

Cost of Sales – Product

Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales.Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the manufacturing costs of Rubraca units recognized as revenue during the three and nine months ended September 30, 2017 were expensed prior to the December 19, 2016 FDA approval, and therefore a minimal amount is included in costs of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories and we expect to use the remaining pre-commercialization inventory for product sales during the fourth quarter of 2017.

Cost of Sales – Intangible Asset Amortization

Research and Development Expenses

Research and development expenses consist of costs incurred for the development of our product candidates and companion diagnostics, which include:

●

license fees and milestone payments related to the acquisition of in-licensed products, which are reported on our Consolidated Statements of Operations and Comprehensive Loss as acquired in-process research and development;

●

employee-related expenses, including salaries, benefits, travel and share-based compensation expense;

~~Table of Contents~~

●

expenses incurred under agreements with contract research organizations (“CROs”) and investigative sites that conduct our clinical trials;

●

the cost of acquiring, developing and manufacturing clinical trial materials;

●

costs associated with non-clinical activities and regulatory operations;

●

market research, disease education and other commercial product planning activities, including the hiring of a ~~U.S.~~ sales and marketing and medical affairs organization in preparation for ~~the~~ commercial launch of ~~rucaparib;~~Rubraca; and

●

activities associated with the development of companion diagnostics for our product candidates.

Research and development costs are expensed as incurred. License fees and milestone payments related to in-licensed products and technology are expensed if it is determined that they have no alternative future use. Costs for certain development activities, such as clinical trials and manufacturing of clinical supply, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors. ~~As a result of the FDA approval of Rubraca and the discontinuation of enrollment in rociletinib, our~~Our research and development expenses decreased ~~in both~~during the three and nine months ended September 30, ~~2017~~2020 compared to the same periods in the prior year. We expect research and development costs to be lower in the full year 2021 compared to full year 2020.

We did not see material disruption to our clinical trials as a result of the COVID-19 pandemic for the three and ~~are expected to decrease for~~nine months ended September 30, 2020 as we completed target enrollment of ATHENA, our largest clinical trial, during

Table of Contents

the second quarter. However, we may see disruption during the remainder of ~~2017 compared~~2020 and into 2021. For example, new patient recruitment in certain clinical studies may be affected and the conduct of clinical trials may vary by geography as some regions are more adversely affected. Additionally, we may slow or delay enrollment in certain trials to ~~prior year as we continue to commercialize Rubraca and commercialization related expenses are classified as selling, general and administrative expenses and not research and development costs.~~manage expenses.

The following table identifies ~~research and development and acquired in-process~~ research and development costs on a program-specific basis for our products under development. Personnel-related costs, depreciation and share-based compensation are not allocated to specific programs, as they are deployed across multiple projects under development and, as such, are separately classified as personnel and other expenses in the table below (in thousands):


		Three months ended September 30,				Nine months ended September 30,
		2020		2019		2020		2019

		(in thousands)
Rucaparib Expenses
Research and development		$	38,672	$	54,268	$	126,329	$	139,802
Rucaparib Total			38,672		54,268		126,329		139,802
FAP Expenses
Research and development			2,182		—		5,026		—
Acquired in-process research and development			—		9,440		—		9,440
FAP Total			2,182		9,440		5,026		9,440
Lucitanib Expenses
Research and development			1,774		1,290		4,605		2,891
Lucitanib Total			1,774		1,290		4,605		2,891
Rociletinib Expenses
Research and development	��		(334)		252		(1,134)		778
Rociletinib Total			(334)		252		(1,134)		778
Personnel and other expenses			20,608		22,086		66,174		67,203
Total		$	62,902	$	87,336	$	201,000	$	220,114

Three months ended September 30,

Nine months ended September 30,


2017

2016

2017

2016

(in thousands)

Rucaparib Expenses

Research and development

$
21,828

$
25,773

$
53,318

$
74,709

Acquired in-process research and development

—

500

—

800

Rucaparib Total

21,828

26,273

53,318

75,509

Lucitanib Expenses

Research and development (a)

(222)

3

(321)

(211)

Lucitanib Total

(222)

3

(321)

(211)

Rociletinib Expenses

Research and development

$
1,752

$
3,040

6,471

40,455

Rociletinib Total

1,752

3,040

6,471

40,455

Personnel and other expenses

15,566

25,522

45,011

81,722

Total

$
38,924

$
54,838

$
104,479

$
197,475

~~(a)This amount reflects actual costs incurred less amounts due from Servier for reimbursable development expenses pursuant to the collaboration and license agreement described in Note 12,~~ ~~License Agreements~~ ~~to our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q.~~

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist principally of salaries and related costs for personnel in executive, commercial, finance, legal, investor relations, human resources and information technology functions. Other ~~selling,~~ general and administrative expenses include facilities expenses, communication expenses, information technology costs, corporate insurance and professional fees for legal, consulting and accounting services. With the FDA approval of Rubraca on December 19, 2016, all sales and marketing expenses associated with Rubraca are included in selling, general and administrative expenses. ~~We anticipate that~~As a result of the COVID-19 pandemic, our U.S. and European sales forces have had physical access to hospitals, clinics, doctors and pharmacies curtailed and/or have been limited, which have decreased sales and marketing expenses during 2020 and will extend to 2021. In addition, due to increased travel restrictions, quarantines, “work-at-home” and “shelter-in-place” orders and extended shutdown of certain non-essential business in the United States, and European and Asia-Pacific countries, in-person conferences and meetings requiring travel have and will continue to decrease resulting in a decrease of our selling, general and administrative ~~expenses~~expenses.

The COVID-19 pandemic has accelerated a preference by oncology practices for more digital programming, including digital, peer-to-peer interactions and reduced in-person promotion. In order to meet these changing preferences, we are adopting a hybrid commercial strategy combining increased digital promotion activities, greater online resources and more peer-to-peer interactions with reduced and more targeted in-person promotion. Accordingly, new tools and performance indicators based on this hybrid approach are being rolled out during the fourth quarter, and the U.S. commercial organization has been reduced in size by approximately 45 employees. Despite increased investment in digital promotion, we anticipate an effect of adopting this hybrid model will ~~continue~~result in annual cost-savings of approximately $10.0 million. We are adopting this strategy in order to ~~increase~~better reach customers in the ~~future in support~~way they want to be reached with the goal of ~~our commercial activities related~~returning to ~~Rubraca.~~growth, especially as the ongoing impact of COVID-19 is reduced.

~~Table of Contents~~

Acquired In-Process Research and Development Expenses

Acquired in-process research and development expenses consist of upfront payments to acquire a new drug compound, as well as subsequent milestone payments. Acquired in-process research and development payments are immediately expensed provided that the drug has not achieved regulatory approval for marketing and, absent obtaining

Table of Contents

such approval, has no alternative future use. Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to intangible asset amortization cost of sales.

~~Change in Fair Value of Contingent Purchase Consideration~~

In connection with the acquisition of EOS in November 2013, we also recorded a purchase consideration liability equal to the estimated fair value of future payments that are contingent upon the achievement of various regulatory and sales milestones. Subsequent to the acquisition date, we re-measure contingent consideration arrangements at fair value each reporting period and record changes in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations. Changes in fair value are primarily attributed to new information about the likelihood of achieving such milestones and the passage of time. In the absence of new information, changes in fair value reflect only the passage of time as we progress towards the achievement of future milestones. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer and lung cancer. At September 30, 2017, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets was zero due to the uncertainty of achieving any of the lucitanib regulatory milestones.

Other Income and Expense

Other income and expense is primarily comprised of foreign currency gains and losses resulting from transactions with ~~contract research organizations (“CROs”), investigational~~CROs, investigative sites and contract manufacturers where payments are made in currencies other than the U.S. dollar. Other expense also includes interest expense recognized related to our convertible senior notes.

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, ~~and~~ revenue and related disclosures. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue, ~~deductions,~~ intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For a description of our critical accounting policies, please see Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2016. There~~2019. Other than the adoption of the new credit losses standard discussed in Note 2, Summary of Significant Accounting Policies, there have not been any material changes to our critical accounting policies since December 31, ~~2016.~~2019.

New Accounting Standards

From time to time, the ~~Financial Accounting Standards Board (“FASB”)~~FASB or other standards-setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through the issuance of an Accounting Standards Update. Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our Consolidated Financial Statements upon adoption.

~~Table of Contents~~

To understand the impact of recently issued guidance, whether adopted or to be adopted, please review the information provided in Note 2, Summary of Significant Accounting Policies, in the Notes to the Unaudited Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

Table of Contents

Results of Operations

Comparison of Three Months Ended September 30, ~~2017~~2020 and ~~2016:~~2019:

The following table summarizes the results of our operations for the three months ended September 30, ~~2017~~2020 and ~~2016~~2019 (in thousands):


					Change
	Three months ended September 30,				Favorable/(Unfavorable)
	2020		2019		$		%
Revenues:
Product revenue	$	38,772	$	37,603	$	1,169		3	%
Operating expenses:
Cost of sales - product		8,438		8,134		(304)		(4)	%
Cost of sales - intangible asset amortization		1,343		1,212		(131)		(11)	%
Research and development		62,902		77,896		14,994		19	%
Selling, general and administrative		38,636		41,811		3,175		8	%
Acquired in-process research and development		—		9,440		9,440		100	%
Other operating expenses		—		5,539		5,539		100	%
Total expenses		111,319		144,032		32,713		23	%
Operating loss		(72,547)		(106,429)		33,882		32	%
Other income (expense):
Interest expense		(6,859)		(5,278)		(1,581)		(30)	%
Foreign currency gain (loss)		633		(229)		862		376	%
Gain on extinguishment of debt		—		18,480		(18,480)		(100)	%
Legal settlement loss		—		(1,750)		1,750		100	%
Other income		79		781		(702)		(90)	%
Other income (expense), net		(6,147)		12,004		(18,151)		(151)	%
Loss before income taxes		(78,694)		(94,425)		15,731		17	%
Income tax benefit		18		350		(332)		(95)	%
Net loss	$	(78,676)	$	(94,075)	$	15,399		16	%

Change

Three months ended September 30,

Favorable/(Unfavorable)


2017

2016

$

%

Product revenue, net

$
16,806

$
—

$
16,806

n/a

Operating expenses:

Cost of sales - product

3,026

—

(3,026)

n/a

Cost of sales - intangible asset amortization

372

—

(372)

n/a

Research and development

38,924

54,338

15,414

28
%
Selling, general and administrative

35,011

9,162

(25,849)

(282)
%
Acquired in-process research and development

—

500

500

n/a

Total expenses

77,333

64,000

(13,333)

(21)
%
Operating loss

(60,527)

(64,000)

3,473

5
%
Other income (expense):

Interest expense

(2,618)

(2,108)

(510)

(24)
%
Foreign currency loss

(44)

(66)

22

33
%
Other income

1,291

252

1,039

(412)
%
Other expense, net

(1,371)

(1,922)

551

29
%
Loss before income taxes

(61,898)

(65,922)

4,024

6
%
Income tax benefit

1,234

227

1,007

(444)
%
Net loss

$
(60,664)

$
(65,695)

$
5,031

8
%

Product ~~Revenue, Net.~~ Revenue. Product revenue for the three months endedSeptember 30, ~~2017 was~~2020 increased compared to the same period in the prior year primarily due to ~~the recognition~~continued growth in sales of ~~$16.8 million of net product revenue from the sale of our first commercial product,~~ Rubraca, which ~~was~~is approved for sale in the United States ~~markets~~and Europe markets. Following successful reimbursement negotiations, we launched Rubraca in Germany and United Kingdom in March 2019, Italy in November 2019, France in February 2020 and Spain in March 2020. In May 2020, the FDA approved Rubraca as a monotherapy treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer and we ~~began shipping on December 19, 2016. Revenue~~have launched Rubraca for prostate cancer in the U.S. Product revenue is recorded net of ~~sales deductions~~variable considerations comprised of rebates, chargebacks and other discounts. ~~Sales deductions represented approximately 7.4%~~Product revenue for the three months ended September 30, 2020 was $33.9 million in the United States and $4.9 million outside of the ~~gross product revenue~~United States. Variable considerations represented 25.1% and 14.1% of the transaction price recognized in the three months ended September 30, ~~2017~~2020 and 2019, respectively. The increase in variable considerations is primarily due to the European National Health Service rebates related to our sales in Europe. Countries in Europe contract larger government rebates and discounts compared to the U.S. contributing to the overall increase in variable considerations. As sales in Europe increase in percentage terms compared to the U.S., variable considerations will also increase. In addition, in the United States, PHS chargebacks increased and beginning in January 2020, we began providing payor rebates, which is included in discounts and fees for the three months September 30, 2020. Amounts are summarized as follows:

Table of Contents


	Three months ended				Three months ended
	September 30, 2020				September 30, 2019
	$		% of Gross Sales		$		% of Gross Sales
	(in thousands)				(in thousands)

Transaction price	$	51,768		100.0%	$	43,775		100.0%
Variable considerations:
Government rebates and chargebacks		9,573		18.5%		3,558		8.1%
Discounts and fees		3,423		6.6%		2,614		6.0%
Total variable considerations		12,996		25.1%		6,172		14.1%
Product revenue	$	38,772		74.9%	$	37,603		85.9%

Three months ended

September 30, 2017

$

% of Gross Sales

(in thousands)

Gross product revenue

$
18,144

100.0%

Sales deductions:

Government rebates and chargebacks

748

4.1%

Discounts and fees

590

3.3%

Total sales deductions

1,338

7.4%

Product revenue, net

$
16,806

92.6%

Cost of Sales – Product. Product cost of sales for the three months ended September 30, ~~2017~~2020 increased compared to the same period in the prior year primarily due to the increase in product revenue. Product cost of ~~$3.0 million~~sales primarily relate to manufacturing, freight and royalties costs associated with Rubraca sales in the period. Manufacturing costs associated with sales in the quarter were expensed as incurred based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, and therefore, a minimal amount is included as product cost of sales for the

~~Table of Contents~~

~~three months ended September 30, 2017.~~ ~~We expect cost of sales to increase in relation to product revenues once we deplete these inventories during the fourth quarter 2017.~~

Cost of Sales – Intangible Asset ~~Amortization~~.Amortization. In the three months ended September 30, ~~2017,~~2020 and 2019, we recognized cost of sales of ~~$0.4~~$1.3 million and $1.2 million, respectively, associated with the amortization of capitalized milestone payments related to the ~~FDA approval~~approvals of ~~Rubraca. Prior to~~Rubraca by the FDA ~~approval on December 16, 2016, all acquired license~~ and ~~milestone payments were expensed as incurred.~~the European Commission.

Research and Development Expenses. Research and development expenses ~~decreased~~decreased during the three months ended September 30, ~~2017~~2020 compared to the same period in the prior year primarily due to lower research and development costs for ~~rucaparib~~Rubraca. The decrease related to our TRITON studies for prostate cancer, diagnostic development costs, clinical supply and ~~rociletinib~~related manufacturing development costs and ~~classification~~personnel costs. These decreases were partially offset by decreased costs related to our ATHENA combination study with Bristol Myers Squibb’s immunotherapy OPDIVO for ovarian cancer. The ATHENA study initiated in the second quarter of ~~commercialization related expenses associated with Rubraca in selling,~~2018 and we completed target enrollment during the second quarter of 2020.

Selling, General and Administrative Expenses. Selling, general and administrative expenses ~~rather than research and development expenses. In~~decreased during the three months ended September 30, ~~2017, Rubraca commercialization costs included in selling, general and administrative expenses were $22.3 million.~~

~~Clinical trial costs for rucaparib were relatively flat~~2020 compared to the same ~~quarter~~period in the prior year due to a ~~year ago as higher~~decrease of $2.2 million in marketing costs ~~from enrollment~~and $1.2 million in ~~ARIEL4, our confirmatory ovarian cancer trials, and enrollment~~stock compensation expenses. In addition, there was a decrease of $1.2 million in our TRITON2 and TRITON3 studies for prostate cancer were largely offset by lower costs for the ARIEL2 and ARIEL3 studies, which have completed enrollment. Clinical supply and related manufacturing development costs were $4.3 million lower than the third quarter of 2016travel due to the ~~capitalization of these costs subsequent to the FDA approval of rucaparib.~~ COVID-19 pandemic. These decreases were partially offset by a $1.2 million increase in legal expenses.

~~Clinical trial costs for rociletinib were $2.7 million lower than the third quarter of 2016 primarily due to the completion of patient enrollment for all~~Acquired In-Process Research and Development Expenses. Upon signing of the ~~TIGER studies~~license and collaboration agreement with 3BP in ~~non-small cell lung cancer.Clinical supply~~September 2019, we made a $9.4 million in upfront payment to 3BP.

Other Operating Expenses. During the three months ended September 30, 2019, we recognized other operating expenses related the write off of some damaged API and costs related ~~manufacturing development costs were $0.7 million higher than the third quarter of 2016 driven by timing of~~to our dedicated production ~~to support our clinical studies.~~train at Lonza.

~~Selling, General and Administrative Expenses.~~ ~~Selling, general and administrative expenses~~Interest Expense. Interest expense increased during the three months ended September 30, ~~2017~~2020 compared to the same period in the prior year primarily due to ~~classification~~the May 2019 financing agreement related to our ATHENA trial.

Gain on Extinguishment of ~~commercialization~~Debt. On August 13, 2019, we repurchased $190.3 million aggregate principal amount of our outstanding 2021 Notes and $2.0 million of accrued interest for an aggregate repurchase price of $171.8 million. This repurchase resulted in the write off of $2.0 million in unamortized debt issuance costs and the recognition of $18.5 million gain on extinguishment of debt.

Legal Settlement Loss. During the three months ended September 30, 2019, we recorded a $1.8 million legal settlement loss due to the difference in the volume weighted average price of our stock over the 10 trading days beginning on June 18, 2019 and the closing stock price on July 1, 2019, the date we issued the shares related ~~expenses associated with Rubraca in selling, general and administrative expenses rather than research and development expenses.~~

to the settlement of a complaint filed by Antipodean Domestic Partners.

Table of Contents

Comparison of Nine Months Ended September 30, ~~2017~~2020 and ~~2016:~~2019:

The following table summarizes the results of our operations for the nine months ended September 30, ~~2017~~2020 and ~~2016~~2019 (in thousands):


					Change
	Nine months ended September 30,				Favorable/(Unfavorable)
	2020		2019		$		%
Revenues:
Product revenue	$	121,223	$	103,699	$	17,524		17	%
Operating expenses:
Cost of sales - product		26,654		21,984		(4,670)		(21)	%
Cost of sales - intangible asset amortization		3,834		3,549		(285)		(8)	%
Research and development		201,000		210,674		9,674		5	%
Selling, general and administrative		123,136		137,601		14,465		11	%
Acquired in-process research and development		—		9,440		9,440		100	%
Other operating expenses		3,805		5,539		1,734		31	%
Total expenses		358,429		388,787		30,358		8	%
Operating loss		(237,206)		(285,088)		47,882		17	%
Other income (expense):
Interest expense		(23,160)		(12,684)		(10,476)		(83)	%
Foreign currency loss		(102)		(648)		546		84	%
Gain on extinguishment of debt		—		18,480		(18,480)		(100)	%
Loss on convertible senior notes conversion		(7,791)		—		(7,791)		(100)	%
Loss on extinguishment of debt		(3,277)		—		(3,277)		(100)	%
Legal settlement loss		—		(26,750)		26,750		100	%
Other income		1,160		5,081		(3,921)		(77)	%
Other income (expense), net		(33,170)		(16,521)		(16,649)		(101)	%
Loss before income taxes		(270,376)		(301,609)		31,233		10	%
Income tax benefit		122		686		(564)		(82)	%
Net loss	$	(270,254)	$	(300,923)	$	30,669		10	%

Change

Nine months ended September 30,

Favorable/(Unfavorable)


2017

2016

$

%

Product revenue, net

$
38,471

$
—

$
38,471

n/a

Operating expenses:

Cost of sales - product

6,920

—

(6,920)

n/a

Cost of sales - intangible asset amortization

1,115

—

(1,115)

n/a
%
Research and development

104,479

196,675

92,196

47
%
Selling, general and administrative

100,384

28,541

(71,843)

(252)
%
Acquired in-process research and development

—

800

800

n/a

Impairment of intangible asset

—

104,517

104,517

n/a

Change in fair value of contingent purchase consideration

—

(24,936)

(24,936)

n/a

Total expenses

212,898

305,597

92,699

30
%
Operating loss

(174,427)

(305,597)

131,170

42.92
%
Other income (expense):

Interest expense

(7,796)

(6,318)

(1,478)

(23.39)
%
Foreign currency loss

(127)

(434)

307

70.74
%
Legal settlement loss, net of insurance receivable

(117,000)

—

(117,000)

n/a

Other income

2,237

473

1,764

373
%
Other expense, net

(122,686)

(6,279)

(116,407)

(1,853.91)
%
Loss before income taxes

(297,113)

(311,876)

14,763

4.73
%
Income tax benefit

2,599

33,467

(30,868)

(92)
%
Net loss

$
(294,514)

$
(278,409)

$
(16,105)

(6)
%

Product ~~Revenue, Net.~~ Revenue. Product revenue for the nine months ended September 30, ~~2017 was~~2020 increased compared to the same period in the prior year primarily due to ~~the recognition~~continued growth in sales of ~~$38.5 million of net product revenue from the sale of our first commercial product,~~ Rubraca, which ~~was~~is approved for sale in the United States ~~markets~~and Europe markets. Following successful reimbursement negotiations, we launched Rubraca in Germany and United Kingdom in March 2019, Italy in November 2019, France in February 2020 and Spain in March 2020. In May 2020, the FDA approved Rubraca as a monotherapy treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer and we ~~began shipping on December 19, 2016. Revenue~~have launched Rubraca for prostate cancer in the U.S. Product revenue is recorded net of ~~sales deductions~~variable considerations comprised of rebates, chargebacks and other discounts. ~~Sales deductions represented approximately 8.2%~~Product revenue for the nine months ended September 30, 2020 was $109.8 million in the United States and $11.4 million outside of the ~~gross product revenue~~United States. Variable considerations represented 22.4% and 14.1% of the transaction price recognized in the nine months ended September 30, ~~2017~~2020 and 2019, respectively. The increase in variable considerations is primarily due to the European National Health Service rebates related to our sales in Europe. Countries in Europe contract larger government rebates and discounts compared to the U.S. contributing to the overall increase in variable considerations. As sales in Europe increase in percentage terms compared to the U.S., variable considerations will also increase. In the United States, PHS chargebacks increased during the nine months ended September 30, 2020 compared to the prior year. In addition, in the United States, GPO discounts increased during the nine months ended September 30, 2020 and beginning in January 2020, we began providing payor rebates, which is included in discounts and fees for the nine months September 30, 2020. Amounts are summarized as follows:

Nine months ended


September 30, 2017


$

% of Gross Sales

(in thousands)

Gross product revenue

$
41,923

100.0%

Sales deductions:

Government rebates and chargebacks

1,820

4.3%

Discounts and fees

1,632

3.9%

Total sales deductions

3,452

8.2%

Product revenue, net

$
38,471

91.8%

Table of Contents


	Nine months ended				Nine months ended
	September 30, 2020				September 30, 2019
	$		% of Gross Sales		$		% of Gross Sales
	(in thousands)				(in thousands)

Transaction price	$	156,227		100.0%	$	120,759		100.0%
Sales deductions:
Government rebates and chargebacks		24,791		15.9%		9,719		8.0%
Discounts and fees		10,213		6.5%		7,341		6.1%
Total sales deductions		35,004		22.4%		17,060		14.1%
Product revenue	$	121,223		77.6%	$	103,699		85.9%

Cost of Sales – Product. Product cost of sales for the nine months ended September 30, ~~2017~~2020 increased compared to the same period in the prior year primarily due to the increase in product revenue. Product cost of ~~$6.9 million~~sales primarily relate to manufacturing, freight and royalties costs associated with Rubraca sales in the period. ~~Manufacturing costs associated with sales in the quarter were expensed as incurred based on our policy to expense costs associated with the manufacture of our~~

~~Table of Contents~~

~~products prior to regulatory approval, and therefore, a minimal amount is included as product cost of sales for the nine months ended September 30, 2017.~~ ~~We expect cost of sales to increase in relation to product revenues once we deplete these inventories during the fourth quarter of 2017.~~

Cost of Sales – Intangible Asset ~~Amortization~~. Amortization. In the nine months ended September 30, ~~2017,~~2020 and 2019, we recognized cost of sales of ~~$1.1~~$3.8 million and $3.5 million, respectively, associated with the amortization of capitalized milestone payments related to the ~~FDA approval~~approvals of ~~Rubraca. Prior to~~Rubraca by the FDA ~~approval on December 19, 2016, all acquired license~~ and ~~milestone payments were expensed as incurred.~~the European Commission.

Research and Development Expenses.Research and development expenses decreased during the nine months ended September 30, ~~2017~~2020 compared to the same period in the prior year primarily due to lower research and development costs for ~~rucaparib and rociletinib and classification of commercialization~~Rubraca. The decrease related expenses associated with Rubraca in selling, general and administrative expenses rather than research and development expenses. In the nine months ended September 30, 2017, Rubraca commercialization costs included in selling, general and administrative expenses were $69.3 million.

~~Clinical trial costs for rucaparib were $1.5 million lower compared~~ to ~~the same period a year ago as higher costs from enrollment in ARIEL4,~~ our ~~confirmatory ovarian cancer trials, and enrollment in our TRITON2 and TRITON3~~TRITON studies for prostate cancer, our ARIEL studies for ovarian cancer, discontinuation of our ATLAS study, diagnostic development costs and personnel costs. These decreases were ~~largely~~partially offset by ~~lower~~decreased costs related to our ATHENA combination study with Bristol Myers Squibb’s immunotherapy OPDIVO for ovarian cancer. The ATHENA study initiated in the ~~ARIEL2~~second quarter of 2018 and ~~ARIEL3 studies, which have~~we completed ~~enrollment. Diagnostic development costs were $4.6 million lower compared to~~target enrollment during the prior year as the prior year included the costs associated with our collaboration with Foundation Medicine, Inc. to develop a novel companion diagnostic test to identify patients most likely to respond to rucaparib. Finally, clinical supply and related manufacturing development costs were $11.3 million lower than 2016 due to the capitalizationsecond quarter of ~~these costs subsequent to the FDA approval of rucaparib.~~ 2020.

~~Clinical trial costs for rociletinib were $21.2 million lower than 2016 primarily due to the completion of patient enrollment for all of the TIGER studies in non-small cell lung cancer.Clinical supply and related manufacturing development costs were $6.5 million lower than 2016 driven by timing of production to support our clinical studies.~~

Selling, General and Administrative Expenses. Selling, general and administrative expenses ~~increased~~decreased during the nine months ended September 30, ~~2017~~2020 compared to the same period in the prior year ~~primarily~~ due ~~mainly~~ to ~~classification~~a decrease of ~~commercialization related expenses associated~~$9.9 million in marketing costs. In addition, there was a decrease of $2.9 million in travel due to the COVID-19 pandemic.

Acquired In-Process Research and Development Expenses. Upon signing of the license and collaboration agreement with ~~Rubraca~~3BP in ~~selling, general and administrative expenses rather than research and development expenses.~~September 2019, we made a $9.4 million in upfront payment to 3BP.

~~Impairment of Intangible Asset.~~Other Operating Expenses. During the ~~second quarter~~three months ended September 30, 2019, we recognized other operating expenses related the write off of ~~2016, we recorded a $104.5 million impairment charge~~some damaged API and costs related to our dedicated production train at Lonza.

Interest Expense. Interest expense increased during the nine months ended September 30, 2020 compared to the ~~IPR&D intangible asset relating~~same period in the prior year due to the May 2019 financing agreement related to our ~~lucitanib product candidate. This reduction~~ATHENA trial. In addition, our convertible senior notes transactions during the year resulted in the ~~estimated fair value~~write off of $4.3 million of unamortized debt issuance costs, which was ~~the result~~recorded as interest expense.

Gain on Extinguishment of Debt. On August 13, 2019, we repurchased $190.3 million aggregate principal amount of our outstanding 2021 Notes and $2.0 million of accrued interest for an aggregate repurchase price of $171.8 million. This repurchase resulted in the write off of $2.0 million in unamortized debt issuance costs and the recognition of $18.5 million gain on extinguishment of debt.

Loss on Convertible Senior Notes Conversion. In January 2020, we completed a registered direct offering of an aggregate 17,777,679 shares of our ~~development partner’s decision~~common stock at a price of $9.25 per share. We used the proceeds of the share offering to ~~discontinue~~repurchase an aggregate of $123.4 million principal amount of 2024 Notes in privately negotiated transactions. In addition, we paid customary fees and expenses in connection with the ~~development~~transactions. This transaction resulted in a loss of ~~lucitanib for breast cancer and lung cancer.~~

~~Change in Fair Value of Contingent Purchase Consideration.~~ ~~Change in fair value of contingent purchase consideration totaled ($24.9)~~$7.8 million for the nine months ended September 30, ~~2016,~~2020.

Loss on Extinguishment of Debt. In April 2020, we entered into a privately negotiated exchange agreement with a Holder of our 2021 Notes, pursuant to which ~~is due~~we issued to ~~a $25.5 million reduction in the fair value~~such Holder of the ~~contingent purchase consideration liability we recorded during the second quarter~~2021 Notes approximately $36.1 million in

Table of ~~2016 due to~~Contents

Additional 2024 Notes of our ~~and our development partner’s decision to discontinue the development~~currently outstanding 2024 Notes in exchange for approximately $32.8 million in aggregate principal of ~~lucitanib for breast cancer and lung cancer.~~2021 Notes held by such Holder, which resulted in a $3.3 million loss on extinguishment of debt.

Legal Settlement ~~Loss, Net of Insurance Receivable.~~Loss. During the second quarter of ~~2017,~~2019, we recorded a ~~$117.0~~one-time charge of $25.0 million to settle a complaint filed by Antipodean Domestic Partners. During the three months ended September 30, 2019, we recorded a $1.8 million legal settlement loss ~~net~~due to the difference in the volume weighted average price of ~~insurance receivable~~our stock over the 10 trading days beginning on June 18, 2019 and the closing stock price on July 1, 2019, the date we issued the shares related to ~~a stipulation agreement of settlement entered into between~~this complaint.

Other Income. Other income decreased during the ~~Clovis Defendants and~~nine months ended September 30, 2020 compared to the ~~Arkin Plaintiffs whereby Clovis will issue~~same period in the ~~plaintiff and participating class members a total consideration comprised of $25.0 million in cash and the issuance of~~ ~~the Settlement Shares. The cash portion of the consideration is expected~~prior year due to ~~be funded by Clovis’ insurance carriers.~~interest income earned on our available-for-sale securities.

Liquidity and Capital Resources

To date, we have principally funded our operations ~~through~~using the net proceeds from public ~~offering~~offerings of our common stock, convertible senior notes offerings and ~~the private placement of convertible debt securities and preferred stock.~~ ~~In January 2017, we sold 5,750,000 shares of~~ our ~~common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses.~~ ~~In June 2017, we sold 3,920,454 shares of~~financing agreement related to our ~~common~~

~~Table of Contents~~

~~stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses.~~ATHENA trial. At September 30, ~~2017,~~2020, we had cash and cash equivalents ~~and available-for-sale securities~~ totaling ~~$628.0~~$224.7 million.

The following table sets forth the primary sources and uses of cash for the nine months ended September 30, ~~2017~~2020 and ~~2016~~2019 (in thousands):


	Nine months ended September 30,
	2020		2019

Net cash used in operating activities	$	(196,675)	$	(253,468)
Net cash provided by investing activities		126,588		126,631
Net cash provided by financing activities		131,808		106,682
Effect of exchange rate changes on cash and cash equivalents		1,148		(240)
Net increase (decrease) in cash and cash equivalents	$	62,869	$	(20,395)

Nine months ended September 30,

2017

2016

Net cash used in operating activities

$
(195,326)

$
(212,005)

Net cash provided by investing activities

29,469

174,304

Net cash provided by financing activities

560,257

2,602

Effect of exchange rate changes on cash and cash equivalents

886

67

Net increase (decrease) in cash and cash equivalents

$
395,286

$
(35,032)

Operating Activities

Net cash used in operating activities ~~for all periods~~ resulted primarily from our net losses adjusted for non-cash items and changes in components of working capital. Net cash used in operating activities was lower during the nine months ended September 30, ~~2017~~2020 compared to the same period in the prior year primarily due to a lower net loss, as adjusted for non-cash items ~~partially offset by increases in the operating assets needed to support the commercialization of Rubraca, most notably~~ related to ~~inventory.~~our debt transactions. In addition, there was a reduction in payments made for inventory during the period.

Investing Activities

Net cash ~~used~~ provided by investing activities for the nine months ended September 30, ~~2017 includes~~2020 included sales of available-for-sale securities of $144.6 million, partially offset by purchases of available-for-sale securities of ~~$180.0~~$10.0 million ~~offset by~~and a milestone payment of $8.0 million.

Net cash ~~from maturities~~used in investing activities for the nine months ended September 30, 2019 included sales of available-for-sale securities of ~~$213.5 million. Net cash provided~~$480.1 million, partially offset by ~~investing activities in the same period in the prior year was mainly the result of maturities~~purchases of available-for-sale securities of ~~$175.0~~$335.1 million ~~in that period.~~ and a milestone payment of $15.8 million.

Financing Activities

Net cash provided by financing activities for the nine months ended September 30, ~~2017 and 2016 includes $14.4~~2020 included proceeds of $246.7 million ~~and $2.6~~from the issuance of common stock, partially offset by a $164.4 million ~~respectively, received from employee stock option exercises.~~payment of our 2024 Notes. In addition, we ~~completed the sale of $545.8~~had $50.0 million ~~of common stock, net of issuance costs, during~~proceeds from borrowings under our financing agreement.

Net cash provided by financing activities for the nine months ended September 30, ~~2017.~~ 2019 included proceeds of $255.0 million from the issuance of our 2024 Notes, $19.0 million proceeds from borrowings under our financing agreement and $2.5 million received from employee stock option exercises and issuance of stock under the employee stock purchase plan, partially offset by a $169.9 million extinguishment of a portion of our 2021 Notes.

Table of Contents

Operating Capital Requirements

In the United States, Rubraca is approved by the FDA for two indications for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Rubraca is also approved by the FDA for prostate cancer. In the EU, Rubraca is approved by the EMA for two indications for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. We expect to incur significant losses for the foreseeable future, as we commercialize Rubraca and expand our selling, general and administrative functions to support the growth in our commercial organization. Additionally, our operating plan for the next 12 months includes a significant investment in inventory to meet the projected commercial requirements for Rubraca. We receive the active pharmaceutical ingredient in Rubraca from one supplier and we experience long lead times associated with its production. Accordingly, we expect to experience a decrease in our liquidity at the beginning of a production cycle and an increase as the inventory produced is sold through.

As of September 30, ~~2017,~~2020, we had cash and cash equivalents ~~and available-for-sale securities~~ totaling ~~$628.0~~$224.7 million and total current liabilities of ~~$219.4~~$124.0 million. In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.6 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including commercial planning and sales and marketing expenses associated with the launch of Rubraca in the United States and, if approved by the EMA, in Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months.

~~Table of Contents~~

Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including but not limited to:

●

the number and characteristics of the product candidates, companion diagnostics and indications we pursue;

●

the achievement of various development, regulatory and commercial milestones resulting in required payments to partners pursuant to the terms of our license agreements;

●

the scope, progress, results and costs of researching and developing our product candidates and related companion diagnostics and conducting clinical and non-clinical trials;

●

the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates and companion diagnostics;

●

the cost of commercialization activities, including marketing and distribution costs;

●

the cost of manufacturing any of our product candidates we successfully commercialize;

●

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and outcome of such litigation; and

●

the timing, receipt and amount of sales, if any, of our product candidates.

In April 2020, we entered into a privately negotiated exchange agreement with a holder (“Holder”) of our 2021 Notes, pursuant to which we issued to such Holder of the 2021 Notes approximately $36.1 million in aggregate principal amount (the “Additional 2024 Notes”) of our currently outstanding 2024 Notes in exchange for approximately $32.8 million in aggregate principal of 2021 Notes held by such Holder (the “Exchange Transaction”). We did not receive any cash proceeds from the Exchange Transaction. In April and May 2020, approximately $24.3 million in principal amount of 2024 Notes were converted into 3,331,870 shares of our common stock at the conversion rate of 137.2213 shares per $1,000 in principal amount of 2024 Notes. In May 2020, we sold 11,090,000 shares of our common stock in a public offering at $8.05 per share. The net proceeds from the offering were $82.8 million, after deducting underwriting discounts and commissions and offering expenses.

In November 2020, we entered into a privately negotiated exchange and purchase agreement with a holder of our 2024 Notes. Pursuant to the agreement, in exchange for approximately $64.8 aggregate principal amount of 2024 Notes held by the holder, we agreed to issue to the holder a number shares of our common stock (the “Exchanged Shares”) utilizing an exchange ratio that is based in part on the daily volume-weighted average prices (“VWAPs”) per share of our common stock during a seven-day pricing period following execution of the agreement.

In addition, pursuant to the agreement, we also agreed to sell to the holder $50.0 million aggregate principal amount of the New 2024 Notes at a purchase price of $1,000 per $1,000 principal amount thereof. Also, we granted the holder a 13-day option to purchase up to an additional $20.0 million aggregate principal amount of New 2024 Notes on the same terms and conditions.

We intend to use the net proceeds from the sale of the New 2024 Notes for general corporate purposes, including repayment, repurchase or refinance of our debt obligations, sales and marketing expenses associated with Rubraca, funding of our development programs, payment of milestones pursuant to our license agreements, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital.

Based on current estimates, we believe that our existing cash, cash equivalents, available-for-sale securities and liquidity available under our financing agreement related to our ATHENA trial will allow us to fund our operating plan through at least the next 12 months.

Table of Contents

Impact of COVID-19 Pandemic

Our ability to generate product revenues for the quarter ended September 30, 2020 was negatively affected by the COVID-19 pandemic due to fewer diagnoses and fewer patients going to in-person office visits as oncology practices and patients continue to adapt to the impact of the virus. As a result of the COVID-19 pandemic, our U.S. and European sales forces have had physical access to hospitals, clinics, doctors and pharmacies curtailed and/or have been limited. Our European launches in Italy, Spain and France occurred in an environment in which our field-based personnel in those countries have not been allowed to visit hospitals since as early as late February. Similarly, we launched Rubraca for prostate cancer in the U.S. beginning in May, but our physical access to hospitals, clinics, doctors and pharmacies has been limited. While commercial new patient starts during the quarter ended September 30, 2020 were consistent with what was observed during the quarter ended June 30, 2020, it is difficult to discern or predict any trend in new patient starts due to the unpredictability of the COVID-19 situation and the changing competitive landscape. European revenues grew from the second quarter ended June 30, 2020 to the third quarter ended September 30, 2020, but with the resurgence of COVID-19 in Europe, as well as the U.S., clinics that had been re-opened to in-person promotion are again limiting access, and it is difficult to predict the impact of the second lockdown on cancer patients and diagnoses.

This curtailment of and/or limited physical access has decreased sales and marketing expenses during 2020 and will likely extend to 2021. In addition, due to increased travel restrictions, quarantines, “work-at-home” and “shelter-in-place” orders and extended shutdown of certain non-essential business in the United States, and European and Asia-Pacific countries, in-person conferences and meetings requiring travel will decrease, resulting in a decrease of our selling, general and administrative expenses. We believe that we have sufficient supply of Rubraca and our product candidates to continue our commercial and clinical operations as planned.

The COVID-19 pandemic has accelerated a preference by oncology practices for more digital programming, including digital, peer-to-peer interactions and reduced in-person promotion. In order to meet these changing preferences, we are adopting a hybrid commercial strategy combining increased digital promotion activities, greater online resources and more peer-to-peer interactions with reduced and more targeted in-person promotion. Accordingly, new tools and performance indicators based on this hybrid approach are being rolled out during the fourth quarter, and the U.S. commercial organization has been reduced in size by approximately 45 employees. Despite increased investment in digital promotion, we anticipate an effect of adopting this hybrid model will result in annual cost-savings of approximately $10.0 million. We are adopting this strategy in order to better reach customers in the way they want to be reached with the goal of returning to growth, especially as the ongoing impact of COVID-19 is reduced.

We did not see material disruption to our clinical trials as a result of the COVID-19 pandemic for the three and nine months ended September 30, 2020 as we completed target enrollment of ATHENA, our largest clinical trial, during the second quarter. However, we may see disruption during the remainder of 2020 and into 2021. For example, new patient recruitment in certain clinical studies may be affected and the conduct of clinical trials may vary by geography as some regions are more adversely affected. Additionally, we may slow or delay enrollment in certain trials to manage expenses.

On March 18, 2020, the Families First Coronavirus Response Act (“FFCR Act”), and on March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act were each enacted in response to the COVID-19 pandemic. The FFCR Act and the CARES Act contain numerous income tax provisions, such as relaxing limitations on the deductibility of interest and the use of net operating losses arising in taxable years beginning after December 31, 2017. We evaluated the impact of this legislation and the income tax provisions did not result in a material cash benefit to us. Future regulatory guidance under the FFCR Act and the CARES Act (as well as under the Tax Cuts and Jobs Act) remains forthcoming, and such guidance could ultimately increase or lessen their impact on our business and financial condition. It is also highly possible that Congress will enact additional legislation in connection with the COVID-19 pandemic, some of which could impact us.

The trading prices for our common stock and of other biopharmaceutical companies have been highly volatile as a result of the coronavirus pandemic. As a result of this volatility and uncertainties regarding future impact of COVID-19 on our business and operations, we may face difficulties raising capital or may only be able to raise capital on unfavorable terms.

Table of Contents

Contractual Obligations and Commitments

For a discussion of our contractual obligations, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our ~~2016~~2019 Annual Report on Form 10-K. ~~There have not been any material changes to such contractual obligations or potential milestone payments since December 31, 2016.~~ For further information regarding our contractual obligations and commitments, see Note ~~14,~~ 15, Commitments and Contingencies to our unaudited consolidated financial statements included elsewhere in this report.

~~ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~
ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk related to changes in interest rates. As of September 30, ~~2017,~~2020, we had cash and cash equivalents ~~and available-for-sale securities~~ of ~~$628.0~~$224.7 million, consisting of bank demand deposits, money market funds and U.S. treasury securities. The primary objectives of our investment policy are to preserve principal and maintain proper liquidity to meet operating needs. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Our available-for-sale securities are subject to interest rate risk and will decline in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our portfolio.

We contract with contract research organizations, ~~investigational~~investigative sites and contract manufacturers globally where payments are made in currencies other than the U.S. dollar. In addition, on October 3, 2016, we entered into a Manufacturing and Services Agreement with a Lonza, a Swiss company, for the ~~production~~long-term manufacture and supply of the ~~active ingredient~~API for Rubraca. Under the terms of this agreement, payments for the supply of the active ingredient in Rubraca as well as scheduled capital program fee payment toward capital equipment and other costs associated with the construction of a dedicated production train will be made in Swiss ~~francs.~~Francs. Once the production ~~facility is~~train became operational in October 2018, we ~~are~~became obligated to pay a fixed facility fee each quarter for the duration of the agreement, which expires on December 31, 2025.

As of September 30, ~~2017, $177.5~~2020, $68.2 million of purchase commitments exist under the ~~Swiss~~ Manufacturing and Services Agreement, which includes the fixed facility fee noted above, and we are required to remit amounts due in Swiss francs. Due to other variables that may exist, it is difficult to quantify the impact of a particular change in exchange rates. However, we estimate that if the value of the US dollar was to strengthen by 10% compared to the value of Swiss franc as of September 30, ~~2017,~~2020, it would decrease the total US dollar purchase commitment under the ~~Swiss~~ Manufacturing and Services Agreement by ~~approximately $16.1~~$15.4 million. Similarly, a 10% weakening of the US dollar compared to the Swiss franc would increase the total US dollar purchase commitment by ~~approximately $19.7~~$3.6 million.

While we periodically hold foreign currencies, primarily Euro, Swiss Franc and Pound Sterling, we do not use other financial instruments to hedge our foreign exchange risk. Transactions denominated in currencies other than the functional

~~Table of Contents~~

currency are recorded based on exchange rates at the time such transactions arise. As of ~~both~~ September 30, ~~2017~~2020 and December 31, ~~2016,~~2019, approximately 1%3% and 4%, respectively, of our total liabilities were denominated in currencies other than the functional currency.

~~ITEM 4.CONTROLS AND PROCEDURES~~
ITEM 4.
CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (“Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the ~~Principal Financial and Accounting~~Chief Finance Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. With the participation of our Chief Executive Officer and ~~Principal Financial and Accounting~~Chief Finance Officer, management performed an evaluation as of September 30, ~~2017~~2020 of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and ~~Principal Financial and Accounting~~Chief Finance Officer concluded that, as of September 30, ~~2017,~~2020, our disclosure controls and procedures were effective at the reasonable assurance level.

Table of Contents

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, ~~2017~~2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3448

Table of Contents

PART II. OTHER INFORMATION

~~ITEM 1.LEGAL PROCEEDINGS~~

ITEM 1.LEGAL PROCEEDINGS

InRociletinib-Related Litigation

On January 22, 2016, the Electrical Workers Local #357 Pension and Health & Welfare Trusts, a purported shareholder of Clovis, filed a purported class action complaint (the “Electrical Workers Complaint”) againstrociletinib, Clovis and certain of its ~~officers, directors, investors~~current and ~~underwriters~~former executives were named in various securities lawsuits, the ~~Superior Court~~largest of ~~the State of California, County of San Mateo (the “Electrical Workers Court”). The Electrical Workers Complaint purports to be asserted on behalf of~~which was a putative class ~~of persons who purchased stock in the July 2015 Offering. The complaint~~ ~~asserted claims under certain provisions~~

~~Table of Contents~~

~~of the Securities Act relating to the July 2015 Offering based on substantially similar allegations to those asserted in the Medina~~ ~~action. On June 30, 2016, the Electrical Workers Plaintiffs filed an amended complaint adding new allegations (the “Amended Complaint”).~~

~~On March 14, 2017, the Clovis Defendants and Antipodean participated in a mediation, which did not result in a settlement.~~

~~The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint. However, there can be no assurance that the defense will be successful.~~

~~Clovis received a letter dated May 31, 2016 from an alleged owner of its common stock, which purports to set forth a demand for inspection of certain of our books and records pursuant to~~ ~~8 Del. C.~~ § 220 (the “Macalinao Demand Letter”). Clovis also received a letter dated December 15, 2016 from a second alleged owner of Clovis common stock, which purports to set forth a similar demand for inspectionIn March 2017, two putative shareholders of the Company’s books and records pursuant to 8 Del. C. § 220 (the “McKenry Demand Letter”). Both the Macalinao Demand Letter and McKenry Demand Letter were purportedly made for the purposes of investigating alleged misconduct at the Company, ~~relating to rociletinib. The Company produced certain books and records in response to the Macalinao Demand Letter and McKenry Demand Letter in January and February 2017, respectively.~~

~~Table of Contents~~

accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint ~~purported to rely on documents produced by the Company in response to the Macalinao Demand Letter and McKenry Demand Letter. The Consolidated Derivative Complaint~~ sought, among other things, an award of money damages.

On October 1, 2019, Vice Chancellor Joseph R. Slights III of the Delaware Chancery Court, issued a Memorandum Opinion granting in part and denying in part defendants’ motions to dismiss. The ~~Company intends~~Supplemental Derivative Complaint was dismissed as to ~~vigorously defend against~~Plaintiffs’ derivative claims for unjust enrichment and insider trading. The Court allowed Plaintiffs’ remaining derivative claim for breach of fiduciary duty to proceed. Defendants filed an answer to the ~~allegations~~Supplemental Derivative Complaint on December 27, 2019.

Table of the State of Delaware (the “Solak Complaint”) against certain directors and an officer of the Company. The Solak Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by adopting a compensation plan that overcompensated the non-employee director defendants, in relation to companies of comparable market capitalization and size. The Solak Complaint also alleged claims of waste of corporate assets and unjust enrichment due to this allegedly wrongful compensation plan. The Solak Complaint sought, among other things, an award of money damages and the imposition of corporate governance reforms.Contents

European Patent Opposition

Oppositions were filed in the granted European counterparts of two patents in the rucaparib camsylate salt/polymorph patent family. An opposition of European patent 2534153 was filed by two opponents on June 20, ~~2017,~~2017. The European Patent Office’s Opposition Division held an oral hearing on December 4, 2018, during which it upheld claims, narrowed from the ~~court~~originally granted patent, to certain crystalline forms of rucaparib camsylate, including, but not limited to, rucaparib S-camsylate Form A, the ~~motion~~crystalline form in Rubraca. Clovis and one opponent, Hexal, appealed the written decision of the European Opposition Division and filed reply appeal briefs in early November 2019. An opposition of European patent 3150610, a divisional patent of European patent 2534153, was filed on April 30, 2020. The divisional patent includes claims directed to ~~stay.~~

use of rucaparib camsylate or rucaparib maleate in a method of inhibiting PARP activity or treating cancer. The ~~Company intends~~grounds of opposition for the divisional patent were lack of novelty, lack of inventive step, added subject matter, and insufficient disclosure – similar grounds on which the parent patent was opposed. It is common for an opponent to ~~vigorously defend against~~raise these grounds in an opposition. During examination, the ~~allegations~~European Patent Office considers all of these grounds and considered the application to comply with the applicable law when granting the patent. In particular, the novelty and inventive step challenges to the divisional patent are based on prior art references (or closely related disclosures) that were cited by the European patent examiner during prosecution of the application. As part of the proceeding, we have the opportunity to submit further arguments and pursue alternative claims in the ~~Guo Complaint, but there~~form of auxiliary requests. While the ultimate results of patent challenges can be ~~no assurance that~~difficult to predict, we believe a number of factors support patentability and we believe a successful challenge of all claims would be difficult. The date for response in the ~~defense will be successful.~~divisional patent is December 28, 2020. In Europe, regulatory exclusivity is available for ten years, plus one year for a new indication, therefore, we have regulatory exclusivity for Rubraca in Europe until 2028, and if an additional indication is approved, until 2029.

In addition, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. The Company is continuing to cooperate with these agencies with respect to their investigations. The proposed settlement of the Medina action does not resolve these inquiries and the Company cannot predict their timing or outcome.

~~Table of Contents~~

~~ITEM 1A.RISK FACTORS~~
ITEM 1A.
RISK FACTORS

Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the risk factors described under the heading “Risk Factors” in Part I, Item 1A of our most recent Annual Report on Form 10-K, in addition to other information contained in or incorporated by reference into this Quarterly Report on Form 10-Q and our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

There ~~have been~~were no material changes to the risk factors included in our previously filed Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2019, other than as highlighted below in connection with the COVID-19 pandemic. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial also may negatively impact our business.

~~ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS~~The outbreak of COVID-19 could materially adversely affect our business.

Table of Contents

On January 30, 2020, the World Health Organization (the “WHO”) declared that the recent novel coronavirus disease (COVID-19) outbreak was a public health emergency of international concern, and on March 11, 2020 the WHO declared the COVID-19 outbreak a pandemic. This has resulted in increased travel restrictions, quarantines, “work-at-home” and “shelter-in-place” orders and extended shutdown of certain non-essential businesses in the United States, and European and Asia-Pacific countries, including countries in which we commercialize Rubraca and countries in which we have planned or active clinical trials. With a renewed rise in the number of cases of the coronavirus in certain parts of the United States and Europe and the ongoing uncertainty regarding future trends in cases, these restrictions, quarantines, shutdowns and other disruption to businesses globally continue to evolve and, in many areas, increase. The effects of the coronavirus are difficult to assess or predict.

The outbreak of COVID-19 has had a major impact on the financial markets, the global economy or the economies of particular countries or regions. Specifically, the COVID-19 outbreak could result in reduced operations of third-party manufacturers upon whom we rely, disrupt our supply chain, or otherwise limit our ability to obtain sufficient materials to manufacture Rubraca and our product candidates. While we believe that we have sufficient supply of Rubraca and our product candidates to continue our commercial and clinical operations as planned, Rubraca and our product candidates, or materials contained therein, come from facilities located in areas impacted by COVID-19 or that may be impacted, as the COVID-19 outbreak or its disruption worsens. If any third party in our supply or distribution chain for materials or finished product are adversely impacted by restrictions resulting from the COVID-19 outbreak, including staffing shortages, production slowdowns and disruptions in delivery systems, our supply chain may be disrupted, limiting our ability to manufacture and distribute Rubraca for commercial sales and our product candidates for our clinical trials and research and development operations. There is no guarantee that the recent COVID-19, or any potential future, outbreak would not impact our future supply chain, which could have a material adverse impact on our clinical trial plans and business operations.

Our sales force has had physical access to hospitals, clinics, doctors and pharmacies curtailed and/or has been limited, which may have a material adverse effect on our future sales. While digital tools are available to our field employees to facilitate remote meetings with healthcare providers, we cannot ensure that these methods will be effective. Additionally, patients who might be currently using Rubraca, or might otherwise be eligible to use our products, may be unable to meet with their healthcare providers in-person, which may reduce the number of prescription refills or new patient starts, affecting our revenues from Rubraca both in our currently approved ovarian cancer indications, as well as impacting our current launch in BRCA-mutant metastatic castration-resistant prostate cancer, which was approved during the second quarter of 2020.

Furthermore, our clinical trials may be affected by the COVID-19 outbreak. Although we did not see material disruption to our clinical trials as a result of the COVID-19 pandemic for the nine months ended September 30, 2020, we could see material disruption during the remainder of 2020 and into 2021. During the second quarter of 2020, we observed a slight decrease in the rate of enrollment in ATHENA, our largest clinical trial, culminating in the completion of target enrollment in ATHENA in that quarter. As the outbreak persists in countries in which we conduct or plan to conduct our clinical trials, activities such as site initiation, patient enrollment, trial data collection, and site monitoring visits may be delayed or stalled due to travel and access restrictions, diversion of healthcare resources toward the COVID-19 outbreak, which we have already started to see in certain of our trial sites, patient or staff unwillingness to visit hospitals and clinics and participate in our trials, or quarantines and other restrictions that may impede patient or staff movement and study drug availability at trial sites, interrupt healthcare services or otherwise prevent patient compliance with clinical trial protocols. Additionally, we may slow or delay enrollment in certain trials to manage expenses.

In addition, COVID-19 could affect our employees, our agents and their employees or the employees of companies with which we do business, thereby disrupting our business operations. We have implemented work-at-home policies and may experience limitations in employee resources. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. The effects of working from home and other burdens imposed by COVID-19 on individuals may impact our employee retention. In addition, our reliance on personnel working from home could increase our cyber security risk, create data accessibility

Table of Contents

concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, manufacturing sites, research or clinical trial sites and other important agencies and contractors.

The trading prices for our common stock and of other biopharmaceutical companies have been highly volatile as a result of the coronavirus pandemic. As a result, we may face difficulties raising capital or which may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the coronavirus could materially and adversely affect our business and the value of our common stock. A number of governments in places where we have operations have adopted stimulus programs to assist businesses effected by COVID-19, including by facilitating lending arrangements. We may access these loan programs for additional working capital although there can be no guarantee that we will obtain any such loans and we do not currently know the terms of such loan programs.

The effectiveness of external parties, including governmental and non-governmental organizations, in combating the spread and severity of COVID-19 could have a material impact on the losses we experience. These events could cause a material adverse effect on our results of operations in any period and, depending on their severity, could also materially and adversely affect our financial condition.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

~~ITEM 3.DEFAULTS UPON SENIOR SECURITIES~~
ITEM 3.
DEFAULTS UPON SENIOR SECURITIES

None.

~~ITEM 4.MINE SAFETY DISCLOSURES~~
ITEM 4.
MINE SAFETY DISCLOSURES

Not Applicable.

~~ITEM 5.OTHER INFORMATION~~
ITEM 5.
OTHER INFORMATION

None.

~~ITEM 6.EXHIBITS~~
ITEM 6.
EXHIBITS

INDEX TO EXHIBITS

o
Exhibit
~~Exhibit~~Number	Exhibit Description
~~Number~~	~~Exhibit Description~~

3.1(5)	Amended and Restated Certificate of Incorporation of Clovis Oncology, Inc.

~~3.2(5)~~3.2(19)	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Clovis Oncology, Inc.

3.3(5)	Amended and Restated Bylaws of Clovis Oncology, Inc.

Table of Contents


3.4(22)	Amendment No. 1 to the Amended and Restated Bylaws of Clovis Oncology, Inc.

4.1(3)	Form of Common Stock Certificate of Clovis Oncology, Inc.

~~4.2(8)~~4.2(7)	Indenture dated as of September 9, 2014, by and between the Company and The Bank of New York Mellon Trust Company, N.A.

4.3(14)	Indenture dated as of April 19, 2018, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee

~~10.1*(4)~~4.4(14)	~~Amended and Restated Strategic License Agreement,~~First Supplemental Indenture dated as of ~~June 16, 2011,~~April 19, 2018, by and between Clovis Oncology, Inc. and ~~Avila Therapeutics, Inc.~~The Bank of New York Mellon Trust Company, N.A.

10.2*4.5(20)	Indenture dated as of August 13, 2019, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee

4.6 (21)	Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

10.1*(4)	License Agreement, dated as of June 2, 2011, by and between Clovis Oncology, Inc. and Pfizer Inc.

~~10.3+~~10.2+(1)	Clovis Oncology, Inc. 2009 Equity Incentive Plan.

~~10.4+~~10.3+(4)	Clovis Oncology, Inc. 2011 Stock Incentive Plan.

10.4+(24)	Clovis Oncology, Inc. 2020 Stock Incentive Plan

10.5+(1)	Form of Clovis Oncology, Inc. 2009 Equity Incentive Plan Stock Option Agreement.

10.6+(4)	Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan Stock Option Agreement.

~~Table of Contents~~

10.7+(23)	~~10.7+~~Form of Clovis Oncology, Inc. 2020 Stock Incentive Plan Option Agreement.

10.8+(23)	Form of Clovis Oncology, Inc. 2020 Stock Incentive Plan Restricted Stock Unit Agreement.

10.9+(3)	Employment Agreement, dated as of August 24, 2011, by and between Clovis Oncology, Inc. and Patrick J. Mahaffy.

~~10.8+~~10.10+(3)	Employment Agreement, dated as of August 24, 2011, ~~between Clovis Oncology, Inc.~~by and ~~Erle T. Mast.~~

~~10.9+(3)~~	~~Employment Agreement, dated as of August 24, 2011,~~ between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

~~10.10+~~10.11+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Paul Klingenstein.

~~10.11+~~10.12+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and James C. Blair.

~~10.12+~~10.13+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Edward J. McKinley.

Table of Contents

~~10.13+~~10.14+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Thorlef Spickschen.

~~10.14+~~10.15+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and M. James Barrett.

~~10.15+~~10.16+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Brian G. Atwood.

~~10.16+~~10.17+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

~~10.17+~~10.18+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Erle T. Mast.

~~10.18+~~10.19+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

~~10.19+(1)~~	~~Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Andrew R. Allen.~~

10.20+~~(4)~~(15)	Clovis Oncology, Inc. 2011 Employee Stock Purchase ~~Plan.~~Plan, as amended.

10.21+(4)	Clovis Oncology, Inc. 2011 Cash Bonus Plan.

10.22+~~(6)~~	~~Indemnification Agreement, dated as of March 22, 2012, between Clovis Oncology, Inc. and Steven L. Hoerter.~~

~~10.23+~~(2)	Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Ginger L. Graham.

~~10.24+~~10.23+(2)	Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Keith Flaherty.

~~10.25(7)~~10.24(6)	Stock Purchase Agreement, dated as of November 19, 2013, by and among the Company, EOS, the Sellers listed on Exhibit A thereto and Sofinnova Capital V FCPR, acting in its capacity as the Sellers’ Representative.

~~Table of Contents~~

~~10.26(7)~~10.25(6)	Development and Commercialization Agreement, dated as of October 24, 2008, by and between Advenchen Laboratories LLC and Ethical Oncology Science ~~S.p.A.~~S.P.A., as amended by the First Amendment, dated as of April 13, 2010 and the Second Amendment, dated as of July 30, 2012.

~~10.27*(7)~~10.26+(10)	~~Collaboration and License Agreement, dated as of September 28, 2012, by and between Ethical Oncology Science S.p.A. and Les Laboratoires Servier and Institut de Recherches Internationales Servier.~~

~~10.28+(12)~~	Indemnification Agreement, effective as of August 3, 2015, between Clovis Oncology, Inc. and Lindsey Rolfe.

10.27+(17)	Amended and Restated Employment Agreement, dated as of February 27, 2019, by and between Clovis Oncology, Inc. and Clovis Oncology UK Limited and Dr. Lindsey Rolfe.

~~10.29+(12)~~10.28+(8)	~~Employment Agreement, dated as of February 25, 2016, by and between Clovis Oncology, Inc. and Lindsey Rolfe.~~

~~10.30+(12)~~	~~Indemnification Agreement, effective as of February 1, 2016, by and between Clovis Oncology, Inc. and Dale Hooks.~~

~~10.31+(12)~~	~~Employment Agreement, effective as of February 1, 2016, by and between Clovis Oncology, Inc. and Dale Hooks.~~

~~10.32+(9)~~	Indemnification Agreement, dated as of February 17, 2016, ~~by and~~ between Clovis Oncology, Inc. and Daniel W. Muehl.

~~10.33+(15)~~10.29+(13)	Employment Agreement, dated as of July 6, 2017, by and between Clovis Oncology, Inc. and Daniel W. Muehl.

~~10.34+(10)~~10.30*(9)	~~Salary Waiver Letter, dated as of May 9, 2016, by and between Clovis Oncology, Inc. and Patrick J. Mahaffy.~~

~~10.35*(11)~~	First Amendment to License Agreement, ~~by and~~ between Clovis Oncology, Inc. and Pfizer Inc., dated as of August 30, 2016.

~~10.36+(13)~~10.31+(11)	Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan RSU Agreement.

Table of Contents



~~10.37(13)~~10.32(11)	Manufacturing Services Agreement, by and between Clovis Oncology, Inc. and Lonza Ltd, dated as of October 3, 2016.

~~10.38(14)~~10.33(12)	Strata Trial Collaboration Agreement, by and between Clovis Oncology, Inc. and Strata Oncology, Inc., dated as of January 30, 2017

10.34+(16)	Indemnification Agreement, dated as of October 11, 2018, between Clovis Oncology, Inc. and Robert W. Azelby.

10.35+(16)	Indemnification Agreement, dated as of October 11, 2018, between Clovis Oncology, Inc. and Richard A. Fair.

10.36+(17)	Employment Agreement, dated as of July 6, 2017, by and between Clovis Oncology, Inc. and Paul Gross.

10.37+(17)	Indemnification Agreement, dated as of September 9, 2016, by and between Clovis Oncology, Inc. and Paul Gross.

10.38(18)	Financing Agreement, dated as of May 1, 2019 among Clovis Oncology, Inc., certain subsidiaries of its subsidiaries named therein, as Guarantors, the Lenders from time to time party thereto, and the Administrative Agent party thereto.
10.39(18)	Pledge and Security Agreement, dated as of May 1, 2019 among each of the Grantors party thereto and the Administrative Agent party thereto.

21.1(15)	List of Subsidiaries of Clovis Oncology, Inc.

31.1	Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2	Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1	Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

~~Table of Contents~~

101

The following materials from Clovis Oncology, Inc.’s Quarterly Report on Form 10-Q for the period ended September 30, ~~2017,~~2020 formatted in ~~XBRL (eXtensible~~Inline Extensible Business Reporting ~~Language)~~Language (“iXBRL”): (i) the Consolidated Statements of Operations and Comprehensive Loss, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Stockholders’ Equity (Deficit), (iv) the Consolidated Statements of Cash Flows and ~~(iv)~~(v) Notes to Unaudited Consolidated Financial Statements.

	~~(1)~~
104	The cover page from Clovis Oncology, Inc.’s Quarterly Report on Form 10-Q for the period ended September 30, 2020 is formatted in iXBRL.

(1)	Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on June 23, 2011.

(2)

~~(2)~~

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on June 14, 2013.

Table of Contents

(3)

~~(3)~~

Filed as an exhibit with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on August 31, 2011.

(4)

~~(4)~~

Filed as an exhibit with Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on October 31, 2011.

(5)

~~(5)~~

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on March 15, 2012.

(6)

~~(6)~~

~~Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-180293) on March 23, 2012.~~

~~(7)~~

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on November 19, 2013.

(7)

~~(8)~~

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on September 9, 2014.

(8)

~~(9)~~

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on April 1, 2016.

(9)

~~(10)~~

~~Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on May 9, 2016.~~

~~(11)~~

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on November 4, 2016.

(10)

~~(12)~~

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 29, 2016.

(11)

~~(13)~~

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 23, 2017.

(12)

~~(14)~~

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on May 4, 2017.

(13)

~~(15)~~

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on July 7, 2017.

(14)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on April 19, 2018.

(15)	Filed as an exhibit with the Registrant’s Current Report on Form 10-Q on August 2, 2018.

(16)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on October 12, 2018.

(17)	Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 28, 2019.

(18)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on May 2, 2019.

(19)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on June 6, 2019.

(20)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on August 13, 2019.

(21)	Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 26, 2020.

(22)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on April 16, 2020.

(23)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on June 4, 2020.

(24)	Filed as an exhibit with the Registrant’s Current Report on Form 10-Q on August 7, 2020.

+ Indicates management contract or compensatory plan.

* Confidential treatment has been granted with respect to portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission.

4156

Table of Contents

SIGNATURES

~~SIGNATURES~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: November ~~2, 2017~~5, 2020	CLOVIS ONCOLOGY, INC.

	By:	/s/ PATRICK J. MAHAFFY
		Patrick J. Mahaffy
		President and Chief Executive Officer; Director

	By:	/s/ DANIEL W. MUEHL
		Daniel W. Muehl
		~~Senior~~Executive Vice President ofand Chief Finance ~~and Principal Financial and Accounting~~ Officer

4257


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	16,498	$	1	$	—	$	16,499


2017 (remaining)	$	372
2018		1,486
2019		1,486
2020		1,486
2021		1,486
Thereafter		13,616
	$	19,932


Balance at December 31, 2016	$	57,192
Change in foreign currency gains and losses		7,061
Balance at September 30, 2017	$	64,253


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value
	Options	Price		Term (Years)	(Thousands)
Outstanding at December 31, 2016	5,520,482	$	42.00
Granted	895,200
Exercised	(439,449)
Forfeited	(217,771)
Outstanding at September 30, 2017	5,758,462	$	46.32	7.3	$	211,301
Vested and expected to vest at September 30, 2017	5,436,766	$	46.10	7.2	$	200,599
Vested and exercisable at September 30, 2017	3,280,881	$	44.09	6.2	$	127,295


					Change
	Three months ended September 30,				Favorable/(Unfavorable)
	2017		2016		$		%

Product revenue, net	$	16,806	$	—	$	16,806		n/a
Operating expenses:
Cost of sales - product		3,026		—		(3,026)		n/a
Cost of sales - intangible asset amortization		372		—		(372)		n/a
Research and development		38,924		54,338		15,414		28	%
Selling, general and administrative		35,011		9,162		(25,849)		(282)	%
Acquired in-process research and development		—		500		500		n/a
Total expenses		77,333		64,000		(13,333)		(21)	%
Operating loss		(60,527)		(64,000)		3,473		5	%
Other income (expense):
Interest expense		(2,618)		(2,108)		(510)		(24)	%
Foreign currency loss		(44)		(66)		22		33	%
Other income		1,291		252		1,039		(412)	%
Other expense, net		(1,371)		(1,922)		551		29	%
Loss before income taxes		(61,898)		(65,922)		4,024		6	%
Income tax benefit		1,234		227		1,007		(444)	%
Net loss	$	(60,664)	$	(65,695)	$	5,031		8	%


	Three months ended
	September 30, 2017
	$		% of Gross Sales
	(in thousands)

Gross product revenue	$	18,144		100.0%
Sales deductions:
Government rebates and chargebacks		748		4.1%
Discounts and fees		590		3.3%
Total sales deductions		1,338		7.4%
Product revenue, net	$	16,806		92.6%


	Nine months ended
	September 30, 2017
	$		% of Gross Sales
	(in thousands)

Gross product revenue	$	41,923		100.0%
Sales deductions:
Government rebates and chargebacks		1,820		4.3%
Discounts and fees		1,632		3.9%
Total sales deductions		3,452		8.2%
Product revenue, net	$	38,471		91.8%